<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JBA</journal-id>
<journal-id journal-id-type="hwp">spjba</journal-id>
<journal-id journal-id-type="nlm-ta">J Biomater Appl</journal-id>
<journal-title>Journal of Biomaterials Applications</journal-title>
<issn pub-type="ppub">0885-3282</issn>
<issn pub-type="epub">1530-8022</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0885328211406459</article-id>
<article-id pub-id-type="publisher-id">10.1177_0885328211406459</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Macroporous bioceramics: A remarkable material for bone regeneration</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Lew</surname><given-names>Kien-Seng</given-names></name>
<xref ref-type="aff" rid="aff1-0885328211406459">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Othman</surname><given-names>Radzali</given-names></name>
<xref ref-type="aff" rid="aff1-0885328211406459">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Ishikawa</surname><given-names>Kunio</given-names></name>
<xref ref-type="aff" rid="aff2-0885328211406459">2</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Yeoh</surname><given-names>Fei-Yee</given-names></name>
<xref ref-type="aff" rid="aff1-0885328211406459">1</xref>
<xref ref-type="corresp" rid="corresp1-0885328211406459"/>
</contrib>
</contrib-group>
<aff id="aff1-0885328211406459"><label>1</label>School of Materials and Mineral Resources Engineering, Universiti Sains Malaysia, Engineering Campus, Nibong Tebal, 14300 Penang, Malaysia</aff>
<aff id="aff2-0885328211406459"><label>2</label>Faculty of Dental Science, Department of Biomaterials, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan</aff>
<author-notes>
<corresp id="corresp1-0885328211406459">Fei-Yee Yeoh, School of Materials and Mineral Resources Engineering, Universiti Sains Malaysia, Engineering Campus, Nibong Tebal, 14300 Penang, Malaysia. Email: <email>srfeiyee@eng.usm.my</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>9</month>
<year>2012</year>
</pub-date>
<volume>27</volume>
<issue>3</issue>
<fpage>345</fpage>
<lpage>358</lpage>
<permissions>
<copyright-statement>© The Author(s) 2011 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2011</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>This review summarises the major developments of macroporous bioceramics used mainly for repairing bone defects. Porous bioceramics have been receiving attention ever since their larger surface area was reported to be beneficial for the formation of more rigid bonds with host tissues. The study of porous bioceramics is important to overcome the less favourable bonds formed between dense bioceramics and host tissues, especially in healing bone defects. Macroporous bioceramics, which have been studied extensively, include hydroxyapatite, tricalcium phosphate, alumina, and zirconia. The pore size and interconnections both have significant effects on the growth rate of bone tissues. The optimum pore size of hydroxyapatite scaffolds for bone growth was found to be 300 µm. The existence of interconnections between pores is critical during the initial stage of tissue ingrowth on porous hydroxyapatite scaffolds. Furthermore, pore formation on β-tricalcium phosphate scaffolds also allowed the impregnation of growth factors and cells to improve bone tissues growth significantly. The formation of vascularised tissues was observed on macroporous alumina but did not take place in the case of dense alumina due to its bioinert nature. A macroporous alumina coating on scaffolds was able to improve the overall mechanical properties, and it enabled the impregnation of bioactive materials that could increase the bone growth rate. Despite the bioinertness of zirconia, porous zirconia was useful in designing scaffolds with superior mechanical properties after being coated with bioactive materials. The pores in zirconia were believed to improve the bone growth on the coated system. In summary, although the formation of pores in bioceramics may adversely affect mechanical properties, the advantages provided by the pores are crucial in repairing bone defects.</p>
</abstract>
<kwd-group>
<kwd>Macroporous bioceramics</kwd>
<kwd>hydroxyapatite</kwd>
<kwd>tricalcium phosphate</kwd>
<kwd>alumina</kwd>
<kwd>zirconia</kwd>
<kwd>bone repair</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-0885328211406459" sec-type="intro"><title>Introduction</title>
<p>Ceramics have been indispensable materials since ancient times. The exploration for new applications of ceramics has been a continuous process until the present. Four decades ago, a revolution occurred in the use of ceramics to improve the quality of life.<sup><xref ref-type="bibr" rid="bibr1-0885328211406459">1</xref></sup> The revolution involved the innovative use of specially designed ceramics for the repair, reconstruction, and replacement of diseased or damaged parts of the body.<sup><xref ref-type="bibr" rid="bibr2-0885328211406459">2</xref><xref ref-type="bibr" rid="bibr3-0885328211406459"/><xref ref-type="bibr" rid="bibr4-0885328211406459"/>–<xref ref-type="bibr" rid="bibr5-0885328211406459">5</xref></sup> Hence, the term ‘bioceramics’ emerged. ‘Bioceramics’ are defined as any ceramic, glass, or glass-ceramic used as a biomaterial, which is a material intended to interface with biological systems to evaluate, treat, augment, or replace any tissue, organ, or function of the body.<sup><xref ref-type="bibr" rid="bibr6-0885328211406459">6</xref></sup> Similarly, the term ‘bioceramics’ also refers to biocompatible ceramic materials that are applicable for biomedical or clinical uses.<sup><xref ref-type="bibr" rid="bibr7-0885328211406459">7</xref></sup> Bioceramics can be polycrystalline (alumina or hydroxyapatite (HA)), bioactive glass, bioactive glass ceramic, or bioactive composite (polyethylene–HA).<sup><xref ref-type="bibr" rid="bibr1-0885328211406459">1</xref></sup></p>
<p>Bioceramics have been widely used in medical applications. Shackelford categorised the applications into three main fields, i.e., orthopaedics, dentistry, and cancer treatment.<sup><xref ref-type="bibr" rid="bibr8-0885328211406459">8</xref></sup> In orthopaedics, bioceramics are used for joint replacement (especially total hip replacement (THR)) as well as defect and fracture repair. The common bioceramics involved are alumina (Al<sub>2</sub>O<sub>3</sub>), partially stabilised zirconia (ZrO<sub>2</sub>), and calcium phosphate (e.g., HA (Ca<sub>10</sub>(PO<sub>4</sub>)<sub>6</sub>(OH)<sub>2</sub>) and tricalcium phosphate (TCP) (Ca<sub>3</sub>(PO<sub>4</sub>)<sub>2</sub>)). In dentistry, traditional dental porcelains composed of mainly leucite and aluminosilicate have been used to repair diseased and decayed teeth. Aside from traditional porcelains, alumina ceramics and glass-ceramic prosthetics, Bioglass®<sup><xref ref-type="bibr" rid="bibr1-0885328211406459">1</xref></sup> implants also play important roles in this application. In cancer treatment, glass beads and ferromagnetic glass ceramics have been used for internal delivery of therapeutic radiation and local thermal treatment of bone tumours, respectively. A typical example of a material used in glass beads is yttria (yttrium(III) oxide) aluminosilicate (YAS) glass. Upon neutron bombardment, yttrium forms a radioactive isotope (Y-90). Such incorporation of radioactive isotope of yttrium during glass melting causes the glass to be highly radioactive with the formation of yttria in the glass composition, which is crucial for cancer radiotherapy. Ferromagnetic glass-ceramics can be obtained by incorporating magnetite in a CaO·SiO<sub>2</sub>-based matrix. After implantation of the glass-ceramic, an alternating magnetic field is applied to create a heating effect that is able to kill cancer cells.<sup><xref ref-type="bibr" rid="bibr8-0885328211406459">8</xref></sup></p>
<p>The dense solid body of bioceramics has extremely high mechanical strength, which makes them preferable for use in areas experiencing a large mechanical load.<sup><xref ref-type="bibr" rid="bibr9-0885328211406459">9</xref></sup> However, the clinical use of dense bioceramics has been limited because of poor bone ingrowth into this material.<sup><xref ref-type="bibr" rid="bibr10-0885328211406459">10</xref></sup> From the aspect of bone tissue growth, porous bioceramics are better than dense bioceramics, even though the latter is suitable for load-bearing purposes. Bone formation was observed to take place earlier at the surface of porous bioceramics,<sup><xref ref-type="bibr" rid="bibr11-0885328211406459">11</xref></sup> where the interconnections of pores can facilitate tissue ingrowth because they provide a good pathway for nutrition transportation.<sup><xref ref-type="bibr" rid="bibr12-0885328211406459">12</xref></sup> Thus, the formation of pores in bioceramics actually broadens their possible applications. To date, there are several review papers that discuss bioceramics in general.<sup><xref ref-type="bibr" rid="bibr1-0885328211406459">1</xref>,<xref ref-type="bibr" rid="bibr13-0885328211406459">13</xref>,<xref ref-type="bibr" rid="bibr14-0885328211406459">14</xref></sup> However, these reviews did not thoroughly cover the topic. In this review, the scope is focused specifically on the development of porous bioceramics and their applications, which have not been reviewed in any other previous publications.</p>
<p>Ever since porous materials emerged and became a popular topic, materials with various ranges of pore size have been studied. Thus, the International Union of Physical and Applied Chemistry has defined various ranges of pore width, i.e., <italic>micropores</italic> (width below 2 nm), <italic>mesopores</italic> (width between 2 and 50 nm), and <italic>macropores</italic> (width above 50 nm),<sup><xref ref-type="bibr" rid="bibr15-0885328211406459">15</xref></sup> which will be applied throughout this review. Micro- and mesopores are sometimes considered nanopores due to their pore size, which falls within the nanometre range.</p>
<sec id="sec2-0885328211406459"><title>Porous bioceramics</title>
<p>The initial study about porous bioceramics had the goal of improving the interfacial area between the implants and the surrounding tissues so as to increase the resistance to the movement of the device in the tissue.<sup><xref ref-type="bibr" rid="bibr1-0885328211406459">1</xref></sup> In addition, the porous network of the HA implant is believed to facilitate bone growth, probably due to the increased surface area and effective fluid circulation.<sup><xref ref-type="bibr" rid="bibr16-0885328211406459">16</xref></sup> Macroporous HA implants with interconnected pores demonstrated a remarkable degree of bone ingrowth.<sup><xref ref-type="bibr" rid="bibr16-0885328211406459">16</xref><xref ref-type="bibr" rid="bibr17-0885328211406459"/>–<xref ref-type="bibr" rid="bibr18-0885328211406459">18</xref></sup></p>
<p>The study of bone growth often involves three essential but confusing terms, i.e., osteoinduction, osteoconduction, and osseointegration. According to Albrektsson and Johansson,<sup><xref ref-type="bibr" rid="bibr19-0885328211406459">19</xref></sup> these three phenomena are interrelated. Osteoinduction is regularly seen in all bone healing processes in which bone formation is induced. From a cellular point of view, osteoinduction comprises the recruitment of immature cells and the stimulation of these cells to develop into preosteoblasts. Osteoconduction is regularly seen in bone implants in which bone grows on a surface or down into pores or channels. Implant materials of low biocompatibility such as copper, silver, and bone cement show little or no osteoconduction. Osseointegration is the stable anchorage of an implant achieved by direct bone-to-implant contact. However, the ingrowth of bone in a porous-coated prosthesis may or may not represent osseointegration.</p>
<p>The effect of pores on the performance of bioceramics has been studied extensively, gradually leading to various discoveries on the importance of pores. In addition to increasing the surface area for better bonding, pores were found to be capable of carrying growth factors for inducing tissue growth and also of delivering drugs to treat diseases.<sup><xref ref-type="bibr" rid="bibr20-0885328211406459">20</xref><xref ref-type="bibr" rid="bibr21-0885328211406459"/><xref ref-type="bibr" rid="bibr22-0885328211406459"/><xref ref-type="bibr" rid="bibr23-0885328211406459"/><xref ref-type="bibr" rid="bibr24-0885328211406459"/><xref ref-type="bibr" rid="bibr25-0885328211406459"/>–<xref ref-type="bibr" rid="bibr26-0885328211406459">26</xref></sup> In different applications, the desired pore characteristics (size, porosity and interconnectivity) vary. The porous bioceramics that have been studied actively belong to the alumina, zirconia, and calcium phosphate families. A few bioceramics, i.e., carbonate apatite (CHA) and fluorapatite (FA) are still being studied to discover the effective method for synthesis of their respective porous versions. Thus, the <italic>in vivo</italic> and <italic>in vitro</italic> performances of their porous versions are yet to be confirmed.</p>
<p>As research continued and advanced over the decades, bioceramics were found to be useful in repairing defects in many parts of the human skeletal structure (<xref ref-type="fig" rid="fig1-0885328211406459">Figure 1</xref>).<sup><xref ref-type="bibr" rid="bibr27-0885328211406459">27</xref></sup> Pores were introduced in bioceramics to enhance their performance by establishing better bonding with tissues and delivering chemicals with sustained release profiles in the human body. To date, various <italic>in vivo</italic> and <italic>in vitro</italic> tests have shown that different biomolecules (e.g., recombinant human osteogenic protein-1 (rhOP-1), bone morphogenetic proteins (BMP)) appear to be deliverable into living organisms for different purposes using porous bioceramics.<sup><xref ref-type="bibr" rid="bibr28-0885328211406459">28</xref>,<xref ref-type="bibr" rid="bibr29-0885328211406459">29</xref></sup>
<fig id="fig1-0885328211406459" position="float"><label>Figure 1.</label><caption><p>Uses of ceramics, glasses, and composites in the body. Source: An Introduction to Bioceramics. Larry L Hench and June Wilson. Copyright © 1993 by World Scientific Publishing Co. Pte. Ltd.<sup><xref ref-type="bibr" rid="bibr27-0885328211406459">27</xref></sup></p></caption><graphic xlink:href="10.1177_0885328211406459-fig1.tif"/></fig></p>
</sec>
</sec>
<sec id="sec3-0885328211406459" sec-type="materials"><title>Materials</title>
<sec id="sec4-0885328211406459"><title>Porous calcium phosphate family</title>
<p>Calcium phosphate (CaP) can be crystallised into mono-, di-, tri-, and tetra-calcium phosphate, HA, CHA, FA, α-TCP, and β-TCP, depending on the Ca/P ratio, the presence of water and impurities, and the synthesis temperature. Porous CaP ceramics had been used as a bone substitute for orthopaedic applications before their potential in drug delivery was discovered. HA and TCP are the two earliest CaP ceramics to be used as a bone substitute due to their compositions, which are similar to the mineral found in human bone.</p>
<p>TCP has a Ca/P ratio of 1.50, which is similar to that of amorphous biological precursors to bone.<sup><xref ref-type="bibr" rid="bibr30-0885328211406459">30</xref></sup> Despite their similarity in composition, TCP and apatites are different, as the former is not found in natural bone. TCP has been developed as a bioactive and bioresorbable bone substitute due to its higher solubility compared toHA.<sup><xref ref-type="bibr" rid="bibr31-0885328211406459">31</xref></sup> In general, TCP is classified into α-tricalcium phosphate (α-TCP) and β-tricalcium phosphate (β-TCP). β-TCP can be converted to α-TCP when it is heated to 1125°C.<sup><xref ref-type="bibr" rid="bibr32-0885328211406459">32</xref></sup> More attention has been focussed on β-TCP than on α-TCP for biomedical applications due to the instability<sup><xref ref-type="bibr" rid="bibr32-0885328211406459">32</xref></sup> and cytotoxicity<sup><xref ref-type="bibr" rid="bibr33-0885328211406459">33</xref></sup> of α-TCP. However, α-TCP can be converted into apatite through a hydrothermal treatment.<sup><xref ref-type="bibr" rid="bibr34-0885328211406459">34</xref></sup> Macroporous β-TCP has been studied intensively as a scaffold for bone growth and as a matrix for various proteins and growth factors. Nevertheless, applications of pure β-TCP to bone defect repair are limited due to the inferior mechanical properties (compressive strength, bending strength, and Young's modulus) of β-TCP when compared to HA.<sup><xref ref-type="bibr" rid="bibr1-0885328211406459">1</xref></sup></p>
<p>HA is an important biomaterial (with a Ca/P ratio of 1.67) present in bones and teeth. In fact, it comprises the primary mineral content of bone (43% by weight),<sup><xref ref-type="bibr" rid="bibr8-0885328211406459">8</xref></sup> which implies that HA is highly biocompatible in nature. Dense HA has been used in orthopaedics or for bone substitutes<sup><xref ref-type="bibr" rid="bibr35-0885328211406459">35</xref><xref ref-type="bibr" rid="bibr36-0885328211406459"/>–<xref ref-type="bibr" rid="bibr37-0885328211406459">37</xref></sup> and dental implants.<sup><xref ref-type="bibr" rid="bibr38-0885328211406459">38</xref></sup> Although HA is not osteoinductive, it possesses good osteoconductive properties as well as a remarkable ability to bind directly to bone.<sup><xref ref-type="bibr" rid="bibr39-0885328211406459">39</xref></sup> Among the calcium phosphate bioceramics, stoichiometric HA dissolves and precipitates at the lowest rate.<sup><xref ref-type="bibr" rid="bibr31-0885328211406459">31</xref></sup> Macroporous HA has been studied intensively since the 1980 s. However, the study of mesoporous and microporous HA for <italic>in vitro </italic>or <italic>in vivo </italic>testing is rather new, although these derivations have a great potential to serve as drug delivery systems. There are also some other types of apatite ceramics, such as CHA and FA. However, among the three porous apatites, interest is mainly focussed on porous HA at present.</p>
<p>The HA and TCP ceramics in the CaP family have their own unique properties that make them important for biomaterials study. For example, HA is superior in the promotion of early bone regeneration, whereas TCP is more bioresorbable than HA.<sup><xref ref-type="bibr" rid="bibr18-0885328211406459">18</xref></sup> Neither of these ceramics is clearly superior to the other, but each provides advantages for certain applications. <xref ref-type="table" rid="table1-0885328211406459">Tables 1</xref> and <xref ref-type="table" rid="table2-0885328211406459">2</xref> show examples of commercially available macroporous HA and β-TCP, respectively.
<table-wrap id="table1-0885328211406459" position="float"><label>Table 1.</label><caption><p>Examples of commercialised macroporous HA blocks/granules.</p></caption>
<graphic alternate-form-of="table1-0885328211406459" xlink:href="10.1177_0885328211406459-table1.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Trade name</th>
<th>Mean pore width (µm)</th>
<th>Mean pore interconnection width (µm)</th>
<th>Manufacturer</th></tr></thead>
<tbody align="left">
<tr>
<td>Apaceram</td>
<td>400</td>
<td>(Not provided)</td>
<td>Asahi Optical Company, Japan</td></tr>
<tr>
<td>BoneceramP</td>
<td>175</td>
<td>(Not provided)</td>
<td>Sumitomo Cement, Japan</td></tr>
<tr>
<td>Endobon</td>
<td>800</td>
<td>(Not provided)</td>
<td>Merck Biomaterial, Germany</td></tr>
<tr>
<td>Interpore 200</td>
<td>230</td>
<td>190</td>
<td>Interpore Int., USA</td></tr>
<tr>
<td>Interpore 500</td>
<td>600</td>
<td>260</td>
<td>Interpore Int., USA</td></tr>
<tr>
<td>Neobone</td>
<td>150</td>
<td>40</td>
<td>Toshiba Ceramics Corp., Japan</td></tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="table2-0885328211406459" position="float"><label>Table 2.</label><caption><p>Examples of commercialised macroporous β-TCP blocks/granules.</p></caption>
<graphic alternate-form-of="table2-0885328211406459" xlink:href="10.1177_0885328211406459-table2.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Trade name</th>
<th>Mean pore width (µm)</th>
<th>Mean pore interconnection width (µm)</th>
<th>Manufacturer</th></tr></thead>
<tbody align="left">
<tr>
<td>Bio-lu</td>
<td>500</td>
<td>150</td>
<td>Shanghai Bio-lu Biomaterials Company Ltd., China</td></tr>
<tr>
<td>Cerasorb</td>
<td>10</td>
<td>(Not provided)</td>
<td>Curasan Inc., Germany</td></tr>
<tr>
<td>chronOS</td>
<td>300</td>
<td>&lt;10</td>
<td>Synthes, Germany</td></tr>
<tr>
<td>Conduit</td>
<td>300</td>
<td>(Not provided)</td>
<td>DePuy Spine Inc., USA</td></tr>
<tr>
<td>OSferion</td>
<td>250</td>
<td>(Not provided)</td>
<td>Olympus Terumo Biomaterials Corp., Japan</td></tr>
</tbody>
</table>
</table-wrap></p>
</sec>
<sec id="sec5-0885328211406459"><title>Macroporous apatite in bone growth</title>
<p>Structurally, the dense sintered HA body is strong, but its use is limited due to its high brittleness and low osteoconductivity.<sup><xref ref-type="bibr" rid="bibr40-0885328211406459">40</xref></sup> On the other hand, although porous HA is weak,<sup><xref ref-type="bibr" rid="bibr41-0885328211406459">41</xref></sup> it is considered a good substitute because it shows good osteoconduction and good bonding with host bone;<sup><xref ref-type="bibr" rid="bibr42-0885328211406459">42</xref></sup> the newly formed bone can invade into the pores and unify with the existing bone. As a result, porous HA ceramics can bond more strongly with the bone.<sup><xref ref-type="bibr" rid="bibr43-0885328211406459">43</xref></sup></p>
<p>Upon investigation of the osteoconductivity difference between dense and porous HA, Yamasaki and Sakai<sup><xref ref-type="bibr" rid="bibr11-0885328211406459">11</xref></sup> reported osteoblast differentiation and new bone formation at the surface of implanted porous HA granules after 3 months of implantation. However, neither ossification nor calcification was found in the specimens treated with dense HA (DHA) granules after 6 months of implantation. It was speculated that the leaching of calcium phosphates from the porous granules or the ion-exchange reactions in the adjacent tissue might have led to these effects. In DHA, granules are presented in such a compact way that the process of granule disintegration by the action of extra-cellular fluid is prevented; this prevents the growth of cells inside the implants.<sup><xref ref-type="bibr" rid="bibr44-0885328211406459">44</xref></sup> Thus, the presence of pores creates more space for physical–chemical interactions between the HA, tissues, and bodily fluid. Such interactions are important for tissue bonding with the porous HA.</p>
<sec id="sec6-0885328211406459"><title>Pore size of HA</title>
<p>Various studies on the relationship between the pore size of macroporous HA ceramics and osteoconduction have been published. The optimum pore size for osteoconduction was 300 µm, although 50 µm would suffice.<sup><xref ref-type="bibr" rid="bibr40-0885328211406459">40</xref></sup> Osteoconduction was greater in HA with a mean pore size of 500 µm than in HA with a pore size of 200 µm.<sup><xref ref-type="bibr" rid="bibr45-0885328211406459">45</xref></sup> However, larger pores would definitely degrade the mechanical properties of HA. Because the mechanical properties of HA are a major concern in bone defect repair, it was demonstrated that a moderate pore size, i.e., 100 µm, was feasible for osteoconduction and should be adapted for porous HA implants, as smaller pore sizes have the advantage of conferring higher mechanical resistance.<sup><xref ref-type="bibr" rid="bibr44-0885328211406459">44</xref></sup> However, the choice of pore size is rather subjective, depending on a balance between the needs for osteoconductivity and favourable mechanical properties. In these studies, the presence of pores enhanced osteoconduction, probably due to the more effective fluid circulation. Such reports helped to identify the suitable pore size range of HA for better osteoconduction. However, these studies did not consider the effects of HA pore interconnections, which could affect cells and vessels with regard to tissue nutrition and new bone formation. Although some studies showed that the mechanical properties of the HA implant improve as bone tissue ingrowth takes place,<sup><xref ref-type="bibr" rid="bibr16-0885328211406459">16</xref>,<xref ref-type="bibr" rid="bibr46-0885328211406459">46</xref></sup> a minimum duration would certainly be needed; therefore, the porous scaffold would still be prone to mechanical failures. Thus, HA implants with suitable pore size are still important to ensure mechanical durability before tissue ingrowth.</p>
<p>In addition to pore size, the depth of the macropores also plays an important role in osteoconduction. When osteoconduction takes place, the depth of tissue ingrowth into the pores is crucial because it determines whether the implant is tightly bonded to the tissues. Ayers et al.<sup><xref ref-type="bibr" rid="bibr47-0885328211406459">47</xref></sup> showed that ingrowth was most affected by the depth into the implant and the duration of implant residence. There seemed to be a maximum ingrowth percentage at each depth in the implant. These maxima decreased with increasing depth in the implant, which indicates that bone ingrowth reaches an equilibrium condition at all depths into porous HA over a sufficient period of time. Similar observations were reported in which bone tissues grew most actively at the entrance of pore channels, and the growth was decreased in the pore channel.<sup><xref ref-type="bibr" rid="bibr48-0885328211406459">48</xref></sup> These studies demonstrated that the pore geometry was important for bone ingrowth because pores with a greater depth provide more room for the ingrowth of bone, which leads to better bonding between the implant and tissues. Therefore, pores with channel-like geometry may be favourable for better bone tissue ingrowth.</p>
</sec>
<sec id="sec7-0885328211406459"><title>Importance of interconnected pores</title>
<p>The interconnections of pores in a porous biomaterial are the pathways between pores (<xref ref-type="fig" rid="fig2-0885328211406459">Figure 2</xref>). They conduct cells and vessels between pores, which leads to better bone ingrowth inside the porous biomaterial.<sup><xref ref-type="bibr" rid="bibr49-0885328211406459">49</xref></sup> The pore structure and morphologies of biomaterials, especially their diameter and interconnectivity, are crucial criteria for developing suitable scaffolds for tissue engineering<sup><xref ref-type="bibr" rid="bibr50-0885328211406459">50</xref></sup> with favourable mechanical properties.<sup><xref ref-type="bibr" rid="bibr12-0885328211406459">12</xref></sup> Besides affecting the osseointegration,<sup><xref ref-type="bibr" rid="bibr51-0885328211406459">51</xref></sup> the three-dimensional porous structure is critical for promotion of cell and tissue ingrowth while maintaining the transport of oxygen and nutrition.<sup><xref ref-type="bibr" rid="bibr12-0885328211406459">12</xref></sup> Interconnected pores are believed to facilitate osteoconduction and interconnected porous HA (IP-HA) implants demonstrated a remarkable degree of bone ingrowth.<sup><xref ref-type="bibr" rid="bibr16-0885328211406459">16</xref><xref ref-type="bibr" rid="bibr17-0885328211406459"/>–<xref ref-type="bibr" rid="bibr18-0885328211406459">18</xref></sup> Bone tissue ingrowth was measured in terms of the speed of bone infiltration and the magnitude of the ultimate volume of bone ingrowth when integration equilibrium was reached.<sup><xref ref-type="bibr" rid="bibr46-0885328211406459">46</xref></sup> Tamai et al.<sup><xref ref-type="bibr" rid="bibr9-0885328211406459">9</xref></sup> demonstrated a 3-mm-deep bone ingrowth from the surface of IP-HA (with an interconnected pore size of 40 µm) after 3 weeks of implantation in a rabbit femur. It was suggested that IP-HA would provide excellent osteoconduction in humans, and no other biomaterials have been described to exhibit this degree of osteoconduction. Given the considerable amount of reports on this topic, the importance and benefit of pore interconnections are obvious.
<fig id="fig2-0885328211406459" position="float"><label>Figure 2.</label><caption><p>(a) Cross-section and (b) longitudinal section of Interpore 200 used by Holmes et al. (1987). Source: Courtesy of Holmes et al.<sup><xref ref-type="bibr" rid="bibr16-0885328211406459">16</xref></sup></p></caption><graphic xlink:href="10.1177_0885328211406459-fig2.tif"/></fig></p>
<p>The volume of initial bone ingrowth in macroporous HA primarily depends on the pore interconnectivity and not pore size,<sup><xref ref-type="bibr" rid="bibr46-0885328211406459">46</xref>,<xref ref-type="bibr" rid="bibr51-0885328211406459">51</xref></sup> probably because the high interconnectivity contributes to a higher rate of cellular invasion andvascularisation, which are critical for the initial ingrowth. However, the interconnections should not have a diameter of less than 10 µm because such size might obstruct the ingrowth of soft tissue including blood vessels, thereby preventing bone formation.<sup><xref ref-type="bibr" rid="bibr52-0885328211406459">52</xref></sup> It was also reported that the diameter of pore interconnections needed to be more than 20 µm for osteoblasts to enter porous ceramics, andmineralised bone formation could be assured for interconnections of more than 50 µm.<sup><xref ref-type="bibr" rid="bibr49-0885328211406459">49</xref></sup> Furthermore, osteoconduction was greater in the HA with larger interconnected pores because it allowed easier penetration of cells and tissues (<xref ref-type="fig" rid="fig3-0885328211406459">Figure 3</xref>).<sup><xref ref-type="bibr" rid="bibr9-0885328211406459">9</xref>,<xref ref-type="bibr" rid="bibr53-0885328211406459">53</xref></sup> Based on these studies, the lower limit for the size of HA pore interconnections was identified. However, the upper limit was not clearly stated. Regardless of the possible compromise in mechanical properties, there should be a maximum size for interconnected pores because a larger interconnection size reduces the degree of interconnectivity, and, thus, the purpose of the interconnecting pores is no longer served.
<fig id="fig3-0885328211406459" position="float"><label>Figure 3.</label><caption><p>Bone ingrowth according to the interconnection size. Source: Courtesy of Flautre et al.<sup><xref ref-type="bibr" rid="bibr53-0885328211406459">53</xref></sup></p></caption><graphic xlink:href="10.1177_0885328211406459-fig3.tif"/></fig></p>
<p>The pore interconnectivity of macroporous HA implants was shown to play an important role in providing strong bonds between the implant and tissues. The interconnected pores in macroporous HA allowed better bone tissue ingrowth that enabled the formation of strong chemical bonds between the implant and bone, as the study of Ryu et al.<sup><xref ref-type="bibr" rid="bibr48-0885328211406459">48</xref></sup> showed that fracture took place inside the ceramics but not at the interface between bone and ceramics. In addition, Omae et al.<sup><xref ref-type="bibr" rid="bibr43-0885328211406459">43</xref></sup> revealed that macroporous HA ceramics with better pore interconnectivity could provide a better adhesion to the grafted tendon both histologically and biomechanically. Better pore interconnectivity brought about an increase in the amount of osseous tissue in the pores at the interface region over time. Thus, tendon was in a direct contact with the osseous tissue in IP-HA. Apparently, the contribution of the pore interconnections here was mainly to provide a larger inner surface area of the implant to maximise the amount of bonds formed, i.e., the amount of adhesion points, which is important to prevent displacement of the implant throughout the healing process.</p>
<p>Although higher porosity adversely affects the mechanical properties of HA implants,<sup><xref ref-type="bibr" rid="bibr49-0885328211406459">49</xref></sup> an interconnected framework of brittle HA shows better mechanical properties after lamination by the ingrowth of an interconnected framework of more ductile bone.<sup><xref ref-type="bibr" rid="bibr16-0885328211406459">16</xref>,<xref ref-type="bibr" rid="bibr46-0885328211406459">46</xref></sup> The compressive strength of the implant was observed to increase steadily in parallel with bone ingrowth in the pores, which gives IP-HA a great advantage as a bone substitute.<sup><xref ref-type="bibr" rid="bibr9-0885328211406459">9</xref></sup> However, several important points must betaken into consideration, such as the duration needed for the porous HA implant to support itself before sufficient bone ingrowth improves the mechanical properties of the implant. To conclude, the advantages of interconnections in porous HA scaffolds may be outlined as follows. The interconnections are able to: (1) provide better transport of oxygen and nutrition for tissue ingrowth, (2) allow a higher rate of cellular invasion and vascularisation for initial ingrowth, and (3) provide a larger inner surface area for better adhesion between implant and tissues.</p>
</sec>
<sec id="sec8-0885328211406459"><title>Protein- and cell-impregnated macroporous HA for bone defects treatment</title>
<p>In addition to osteoconduction, macropores and their interconnections in HA are also important for osteoinduction.<sup><xref ref-type="bibr" rid="bibr29-0885328211406459">29</xref></sup> It was confirmed that calcium phosphates can provide osteoinduction because their microstructure may act as a carrier or absorbent of osteogenic agents (such as BMP).<sup><xref ref-type="bibr" rid="bibr54-0885328211406459">54</xref>,<xref ref-type="bibr" rid="bibr55-0885328211406459">55</xref></sup> The characteristics of the microstructure are crucial to allow BMP to reach the threshold concentration required for osteoinduction<sup><xref ref-type="bibr" rid="bibr56-0885328211406459">56</xref>,<xref ref-type="bibr" rid="bibr57-0885328211406459">57</xref></sup> because the abundance of the pore interconnections directly affects the duration needed to meet the threshold level. Similarly, osteoinductive rhOP-1 carried by the macropores of HA could also improve the healing of segmental bone defects.<sup><xref ref-type="bibr" rid="bibr28-0885328211406459">28</xref></sup> However, for large-scale applications, this procedure is rather expensive. For the osteoconduction of macroporous HA, the process could be enhanced by hybridising IP-HA (interconnections of 10–90 µm) with cultured marrow stromal stem cells.<sup><xref ref-type="bibr" rid="bibr58-0885328211406459">58</xref></sup> A study conducted by Nakasa et al.<sup><xref ref-type="bibr" rid="bibr59-0885328211406459">59</xref></sup> also showed that the combination of fibroblast growth factor-2 and vascular bundle implantation could enhance the growth of new blood vessels in an IP-HA and subsequently accelerate bone formation. All these studies proved that macroporous HA has a high potential as a carrier for various chemicals, and it does not alter the properties of the chemical carried.</p>
</sec>
</sec>
<sec id="sec9-0885328211406459"><title>Macroporous <bold>β</bold>-TCP in bone growth</title>
<p>To date, there have been no published studies that compare dense and porous β-TCP in bone defect treatment. However, the contribution of the greater porosity of β-TCP was outlined by Knabe et al.,<sup><xref ref-type="bibr" rid="bibr60-0885328211406459">60</xref></sup> where enhanced bone formation, particle degradation, and matrix mineralisation were observed in the β-TCP with higher porosity. Such findings show agreement with those observed in porous HA, which again points out that the presence of pores in scaffolds is beneficial for the growth of bone tissues.</p>
<sec id="sec10-0885328211406459"><title>Macropores and osteoconduction</title>
<p>One of the early studies on macroporous β-TCP for artificial bones showed that new bone tissues had direct contact with the scaffold and could be traced in the pores.<sup><xref ref-type="bibr" rid="bibr61-0885328211406459">61</xref></sup> Similarly, macroporous β-TCP exhibited prominent osteoconductive and bioresorbable properties in human adult bone.<sup><xref ref-type="bibr" rid="bibr62-0885328211406459">62</xref></sup> In fact, the potential of the β-TCP graft to promote bone formation was determined by its porosity, whereby the pores could be infiltrated by osteogenic precursor cells or osteoblasts that eventually support the laying down of osteoid.<sup><xref ref-type="bibr" rid="bibr63-0885328211406459">63</xref></sup></p>
<p>Various studies regarding macroporous β-TCP indicate that the presence of pores is undeniably beneficial to osteoconduction. However, some studies implied that the rate of bone tissue formation on macroporous β-TCP was lower when compared to other materials such as macroporous HA<sup><xref ref-type="bibr" rid="bibr18-0885328211406459">18</xref></sup> and autologous bone, although the local resorption of β-TCP might contribute to the osteoblastic differentiation.<sup><xref ref-type="bibr" rid="bibr64-0885328211406459">64</xref></sup> Osteogenic connective tissue cells were found in and around the macroporous β-TCP only after 6 months.<sup><xref ref-type="bibr" rid="bibr64-0885328211406459">64</xref></sup> Although macroporous β-TCP was capable of generating bone thickness similar to that of the autologous bone, the rate of bone formation was somewhat delayed.<sup><xref ref-type="bibr" rid="bibr65-0885328211406459">65</xref></sup> Theauthors attributed this to the osteoconductive, but not the osteoinductive, properties of this material, but a detailed explanation for this phenomenon is not available yet. However, when compared to other materials, the difference in the pore characteristics (especially interconnectivity) might be one of the reasons for the different rates observed.</p>
</sec>
<sec id="sec11-0885328211406459"><title>Protein- and cell-impregnated macroporous <bold>β</bold>-TCP for bone defects treatment</title>
<p>Similarly to macroporous HA, the presence of macropores created an opportunity to render osteoinductive properties to macroporous β-TCP in repairing bone defects. Many studies attempted to impregnate the macropores on β-TCP with proteins such as recombinant human bone morphogenetic protein-2 (rhBMP-2),<sup><xref ref-type="bibr" rid="bibr66-0885328211406459">66</xref><xref ref-type="bibr" rid="bibr67-0885328211406459"/><xref ref-type="bibr" rid="bibr68-0885328211406459"/>–<xref ref-type="bibr" rid="bibr69-0885328211406459">69</xref></sup> insulin-like growth factor-I (IGF-I),<sup><xref ref-type="bibr" rid="bibr70-0885328211406459">70</xref></sup> and transforming growth factor-β3 (TGF-β3)<sup><xref ref-type="bibr" rid="bibr71-0885328211406459">71</xref></sup> as well as bone marrow stromal cells (BMSCs).<sup><xref ref-type="bibr" rid="bibr72-0885328211406459">72</xref>,<xref ref-type="bibr" rid="bibr73-0885328211406459">73</xref></sup> Macroporous β-TCP was found to be an important matrix for vectorising the osteoinductive proteins and releasing them locally. The importance of pores for such impregnation was shown by a recent study in which the β-TCP that underwent treatment to achieve better porosity exhibited better protein adsorption than the untreated β-TCP.<sup><xref ref-type="bibr" rid="bibr74-0885328211406459">74</xref></sup> In this case, the efficacy of the implants was determined by the degree of bone formation and mass reduction of β-TCP.<sup><xref ref-type="bibr" rid="bibr67-0885328211406459">67</xref></sup> In addition, reports showed that impregnation with rhBMP-2 and TGF-β3 was able to enhance the rate of β-TCP bioresorption,<sup><xref ref-type="bibr" rid="bibr69-0885328211406459">69</xref>,<xref ref-type="bibr" rid="bibr71-0885328211406459">71</xref></sup> which was an advantage in such cases. The possible reasons for the enhanced bioresorption rate were explained by Hoshino et al.<sup><xref ref-type="bibr" rid="bibr69-0885328211406459">69</xref></sup> However, a study showed that the impregnation of platelet-rich plasma in macroporous β-TCP did not induce a significant amount of new bone formation.<sup><xref ref-type="bibr" rid="bibr75-0885328211406459">75</xref></sup></p>
<p>Besides being a suitable matrix for rhBMP-2, macroporous β-TCP also exhibited remarkable osteoinductive properties after being impregnated with rhBMP-2.<sup><xref ref-type="bibr" rid="bibr66-0885328211406459">66</xref><xref ref-type="bibr" rid="bibr67-0885328211406459"/><xref ref-type="bibr" rid="bibr68-0885328211406459"/>–<xref ref-type="bibr" rid="bibr69-0885328211406459">69</xref></sup> Macroporous β-TCP showed greater formation of new bone when a higher dose of rhBMP-2 was impregnated,<sup><xref ref-type="bibr" rid="bibr66-0885328211406459">66</xref></sup> and the minimum concentration of rhBMP-2 to induce bone formation after 6 weeks was 0.0025 wt%.<sup><xref ref-type="bibr" rid="bibr67-0885328211406459">67</xref></sup> Additionally, macroporous β-TCP impregnated with IGF-I or TGF-β3 was able to stimulate bone growth and enhance bone formation.<sup><xref ref-type="bibr" rid="bibr70-0885328211406459">70</xref>,<xref ref-type="bibr" rid="bibr71-0885328211406459">71</xref></sup> Although the optimal dosage of the impregnated protein in macroporous β-TCP was important,<sup><xref ref-type="bibr" rid="bibr67-0885328211406459">67</xref><xref ref-type="bibr" rid="bibr68-0885328211406459"/>–<xref ref-type="bibr" rid="bibr69-0885328211406459">69</xref></sup> the relationship between the pore characteristics of macroporous β-TCP and its protein release rate was not studied in depth; attention was paid more to the outcomes, i.e., the occurrence of new bone formation and the time taken for bone formation to occur. Because macroporous β-TCP concurrently undergoes <italic>in vivo</italic> bioresorption and protein release, it is speculated that the release rate of the impregnated substance will not be consistent. However, macroporous β-TCP has been a competent porous bioceramic for proteins delivery to date, and to our knowledge, there have been no reports on the alteration of protein properties.</p>
<p>Macroporous β-TCP could also be impregnated with BMSCs for mandibular reconstruction, and new bone formation was observed 4 weeks after surgery, in contrast to treatment with β-TCP alone, for which only minimal bone formation with almost fibrous connectivity was observed.<sup><xref ref-type="bibr" rid="bibr72-0885328211406459">72</xref></sup> In addition, the efficacy of macroporous β-TCP impregnated with BMSC in treating the posterior spine was as high as 95%.<sup><xref ref-type="bibr" rid="bibr73-0885328211406459">73</xref></sup> It was reported that the compressive strength of a macroporous β-TCP scaffold could be improved significantly by cell seeding.<sup><xref ref-type="bibr" rid="bibr72-0885328211406459">72</xref></sup> This finding showed that macroporous β-TCP with BMSC impregnation could be used to repair and temporarily support skeletal parts exposed to loading due to enhanced mechanical properties of the β-TCP. However, cell-impregnated β-TCP and HA with similar pore characteristics showed comparable osteogenic ability,<sup><xref ref-type="bibr" rid="bibr76-0885328211406459">76</xref></sup> which suggested that the biocompatibility of macroporous β-TCP for the impregnated cells was equal to that of macroporous HA. It is important that in addition to not altering the properties of impregnated proteins, the macroporous β-TCP is biocompatible for the impregnated cells. Both protein and cell impregnations in macroporous β-TCP have respective advantages depending on requirements, i.e., healing speed and mechanical strength.</p>
<p>From the past studies, porous β-TCP has been developed as a matrix for osteoinductive proteins and cells. The purpose of applying macroporous β-TCP impregnated with proteins or cells is mainly to replace the use of autogenous bone grafts in promoting local bone formation due to disadvantages associated with autogenous bone grafting, including a limited source of donor bone coupled with donor site morbidities.<sup><xref ref-type="bibr" rid="bibr67-0885328211406459">67</xref></sup> Macroporous β-TCP is a potential replacement candidate due to its bioresorbable nature and, more importantly, its osteoinductive properties after suitable impregnation. The relatively higher bioresorption rate of β-TCP seems to facilitate its release of various impregnated substances and allows it to be replaced by natural bone, which probably explains why macroporous β-TCP, rather than macroporous HA (which hardly bioresorbs), was favoured as a candidate to be impregnated with agents able to induce or enhance the bone growth. The number of reports for macroporous β-TCP in this particular application is higher than that of macroporous HA.</p>
</sec>
</sec>
<sec id="sec12-0885328211406459"><title>Macroporous alumina</title>
<p>Alumina is widely used for biomedical applications due to its good mechanical properties from excellent strength, promising fracture toughness, high wear resistance, good biocompatibility, to excellent corrosion resistance.<sup><xref ref-type="bibr" rid="bibr77-0885328211406459">77</xref></sup> High-density, high-purity (&gt;99.5%) alumina (Al<sub>2</sub>O<sub>3</sub>) was the first bioceramic widely used in the medical field.<sup><xref ref-type="bibr" rid="bibr1-0885328211406459">1</xref></sup> However, it has a much lower tensile strength (259 MPa) than compressive strength (2965 MPa) due to its brittleness (i.e., it cannot undergo plastic deformation like metals and plastics),<sup><xref ref-type="bibr" rid="bibr35-0885328211406459">35</xref></sup> which is a disadvantage for orthopaedic load-bearing applications.</p>
<p>Boutin<sup><xref ref-type="bibr" rid="bibr3-0885328211406459">3</xref></sup> was the first to use alumina ceramic materials as bearing surfaces in artificial hips in the early 1970 s.<sup><xref ref-type="bibr" rid="bibr78-0885328211406459">78</xref>,<xref ref-type="bibr" rid="bibr79-0885328211406459">79</xref></sup> Most of the alumina used for implant applications is either a polycrystalline solid of high density and purity or an artificially grown colourless single crystal similar to sapphire or ruby.<sup><xref ref-type="bibr" rid="bibr35-0885328211406459">35</xref></sup> Alumina is regarded as an almost-inert bioceramic, and, thus, a fibrous tissue of variable thickness is expected to be formed around it after implantation.<sup><xref ref-type="bibr" rid="bibr1-0885328211406459">1</xref></sup> However, Eckert et al.<sup><xref ref-type="bibr" rid="bibr80-0885328211406459">80</xref></sup> showed that bone tissues could be formed on macroporous (pore width &gt;50 nm) alumina. Previously, <italic>in vivo</italic> experiments with porous polymers showed that porosity can support the maintenance of vascularisation at the surface of the implanted materials,<sup><xref ref-type="bibr" rid="bibr81-0885328211406459">81</xref></sup> which indicates that the porosity of alumina ceramics may have effects similar to those observed for implanted polymers and explains the observation that dense alumina implants were normally surrounded by fibrous tissue capsules but porous alumina allowed the apposition of physiological tissue.<sup><xref ref-type="bibr" rid="bibr80-0885328211406459">80</xref></sup></p>
<sec id="sec13-0885328211406459"><title>Bioactivity of macroporous alumina</title>
<p>Macroporous alumina shaped as a hollow-sphere with a central opening was developed to allow ingrowth of vascularised tissues (<xref ref-type="fig" rid="fig4-0885328211406459">Figure 4</xref>).<sup><xref ref-type="bibr" rid="bibr80-0885328211406459">80</xref></sup> No long-term fibrotic tissue capsule formation was observed from the tissue reactions at the external surface of the porous alumina, which was contrary to dense alumina in which fibrotic tissue was formed in the surroundings. In addition, the porous alumina cell carriers were able to support cells for long periods because there was no obstruction ofnutrient diffusion through the porous carrier. Macroporous alumina was a non-toxic scaffold based on <italic>in vitro</italic> tests, and it also provided favourable sites for cell attachment after being coated with HA.<sup><xref ref-type="bibr" rid="bibr82-0885328211406459">82</xref></sup> From these studies, it was apparent that the shape and architecture of scaffolds were important factors for the establishment of a vascular supply for tissue-engineered transplants. Even a bioinert bioceramic can be used as a matrix for the growth of vascularised tissues if it has an overall suitable morphology, especially on the surface.
<fig id="fig4-0885328211406459" position="float"><label>Figure 4.</label><caption><p>(i) View of a macroporous alumina cell carrier. (ii) A section through a cell carrier exposes: (a) a central opening with smoothly rounded rims, (b) a compartmentalized structure in the bottom, and (c) a porous alumina bulk material. Source: Courtesy of Eckert et al.<sup><xref ref-type="bibr" rid="bibr80-0885328211406459">80</xref></sup></p></caption><graphic xlink:href="10.1177_0885328211406459-fig4.tif"/></fig></p>
<p>A thin macroporous alumina layer (with a thickness and pore size of 60 µm and 200 nm, respectively) was found to be useful when placed on top of a titanium implant because it could reduce the friction considerably while maintaining the lightness and good elastic modulus of titanium. Such coatings on titanium could alsoprevent the corrosion of the titanium, which might lead to the deposition of metal in the body.<sup><xref ref-type="bibr" rid="bibr83-0885328211406459">83</xref></sup> Surprisingly, the macropores on the alumina layer could be impregnated with combinations of materials and particles of various sizes through capillary action,<sup><xref ref-type="bibr" rid="bibr84-0885328211406459">84</xref></sup> and, thus, bioactive properties can be rendered to the macroporous alumina by filling the pores with bioactive materials such as HA.<sup><xref ref-type="bibr" rid="bibr83-0885328211406459">83</xref></sup> Such macroporous alumina membranes provide a good surface for rapid osteoblastic cell growth. The amount of aluminium ions leaking out from the membranes was low and was in fact in the range to stimulate osteoblast proliferation and differentiation, instead of affecting the bone mineralisation negatively.<sup><xref ref-type="bibr" rid="bibr83-0885328211406459">83</xref></sup> Thus, the application of macroporous alumina coating was able to improve the overall mechanical properties of the scaffold and to enable the impregnation of bioactive materials for osteoconduction and osteoinduction purposes. Indirectly, such a coating was capable of conferring bioactivity to a bioinert metal scaffold. Despite the high availability of aluminium and the simplicity of the anodisation process used for such coating, the studies of this application are not extensive, likely due to the high cost of titanium.</p>
</sec>
</sec>
<sec id="sec14-0885328211406459"><title>Macroporous zirconia</title>
<p>Phase-stabilised zirconia has become a popular alternative to alumina as a structural ceramic,<sup><xref ref-type="bibr" rid="bibr84-0885328211406459">84</xref></sup> especially in THR applications, because of its substantially higher fracture toughness (10.5 MPa m<sup>1/2</sup>).<sup><xref ref-type="bibr" rid="bibr35-0885328211406459">35</xref></sup> The fracture strength of zirconia ceramic heads is approximately double that of alumina heads (5.4 MPa m<sup>1/2</sup>).<sup><xref ref-type="bibr" rid="bibr85-0885328211406459">85</xref></sup> In order to achieve better mechanical properties, yttrium is added into the crystal structure of zirconia in the form of yttrium (III) oxide to form yttria-stabilised zirconia (YSZ). In orthopaedic implants, YSZ is commonly used due to its combination of outstanding mechanical properties, biocompatibility, and wear behaviour against polyethylene. The interest in zirconia is derived from its high fracture toughness and tensile strength. These improved properties make it possible to manufacture femoral heads for total hip prostheses that are smaller than the present generation of alumina heads.<sup><xref ref-type="bibr" rid="bibr1-0885328211406459">1</xref></sup></p>
<p>The use of zirconia (ZrO<sub>2</sub>) for biomedical applications was first reported by Helmer and Driskell<sup><xref ref-type="bibr" rid="bibr86-0885328211406459">86</xref></sup> in 1969. The first paper reporting the use of zirconia to manufacture ball heads for THR, which is the current main application of this bioceramic, was published by Christel et al.<sup><xref ref-type="bibr" rid="bibr87-0885328211406459">87</xref></sup> in 1988. Overall, by 2006, there were more than 600,000 zirconia femoral heads had been implanted worldwide, mainly in the US and in Europe.<sup><xref ref-type="bibr" rid="bibr88-0885328211406459">88</xref></sup></p>
<p>The number of published works regarding the application of macroporous zirconia in biomedicine is limited. In a series of studies conducted by Kim et al.,<sup><xref ref-type="bibr" rid="bibr89-0885328211406459">89</xref><xref ref-type="bibr" rid="bibr90-0885328211406459"/><xref ref-type="bibr" rid="bibr91-0885328211406459"/>–<xref ref-type="bibr" rid="bibr92-0885328211406459">92</xref></sup> macroporous zirconia was used as the substrate for a HA coating to be applied as a bone scaffold (<xref ref-type="fig" rid="fig5-0885328211406459">Figure 5</xref>). Macroporous zirconia was chosen as a substrate because its mechanical strength is approximately seven times higher than that of HA,<sup><xref ref-type="bibr" rid="bibr89-0885328211406459">89</xref></sup> which would help to mitigate the poor mechanical properties of calcium phosphates. In addition, a macroporous scaffold is believed to be able to improve the osteoconductivity of the coating system.<sup><xref ref-type="bibr" rid="bibr90-0885328211406459">90</xref></sup> Thus, the idea behind this approach was to combine the bioactivity of HA with the mechanical benefits of zirconia to produce a strong and bioactive macroporous scaffold.
<fig id="fig5-0885328211406459" position="float"><label>Figure 5.</label><caption><p>Morphologies (cross-section view) of a coated ZrO<sub>2</sub> scaffold; the coating layer consisted of HA + TCP outer and FA inner layers. Source: Courtesy of Kim et al.<sup><xref ref-type="bibr" rid="bibr90-0885328211406459">90</xref></sup></p></caption><graphic xlink:href="10.1177_0885328211406459-fig5.tif"/></fig></p>
<sec id="sec15-0885328211406459"><title>Macroporous zirconia as a substrate for HA coatings</title>
<p>To overcome the drawbacks in the mechanical properties of HA, a highly porous zirconia scaffold coated with HA was designed by Kim et al.<sup><xref ref-type="bibr" rid="bibr92-0885328211406459">92</xref></sup> The high-porosity (84–87%) zirconia framework possessed excellent compressive strength (7–8 MPa), which was unachievable in the case of pure apatite scaffolds (74% porosity with a strength of 2 MPa). They investigated for the first time the <italic>in vivo</italic> performance of macroporous zirconia scaffolds coated with a HA layer. Overall, new bone formation occurred effectively within the pore channels of the apatite-coated zirconia scaffolds, and the results were comparable to those of the pure HA scaffold. Better bone regeneration was also exhibited by the scaffold with relatively higher porosity, which indicates that increased porosity should favour the bone regeneration ability of the scaffold. However, the pore size did not show any significant influence on the bone regeneration ability. The authors suggested that zirconia with higher porosity and pore interconnectivity would not only minimise the amount of graft material required, but also increase the specific surface area for cell attachment and tissue ingrowth, thereby facilitating the uniform distribution of cells and the adequate transport of nutrients.</p>
<p>The combination of the best features of two different materials has led to the enhancement of properties and innovative development of bioceramics. Kim et al.<sup><xref ref-type="bibr" rid="bibr92-0885328211406459">92</xref></sup> showed that a highly porous bioceramic scaffold which exhibited good mechanical properties and bioactivity could be effectively produced by a coating method. The main advantage of this method was that the coating would not cause a significant reduction of the porosity in the substrate. Similar to HA, β-TCP, and alumina, it was suggested that the macroporous zirconia scaffolds with a higher porosity exhibit enhanced bone formation ability. However, some drawbacks in the mechanical properties may result from an increased porosity. Therefore, the selection of a scaffold should be made by finding a compromise between the mechanical properties and bone formation ability.</p>
</sec>
</sec>
</sec>
<sec id="sec16-0885328211406459"><title>Future and potential development of porous bioceramics</title>
<p>Of all the porous bioceramics reviewed, none seem to show significant osteoinductivity without impregnation of bioactive agents (e.g., growth factors). <sup><xref ref-type="bibr" rid="bibr28-0885328211406459">28</xref>,<xref ref-type="bibr" rid="bibr39-0885328211406459">39</xref>,<xref ref-type="bibr" rid="bibr54-0885328211406459">54</xref>,<xref ref-type="bibr" rid="bibr65-0885328211406459">65</xref></sup> In fact, the key to enable osteoinductive properties in the porous bioceramics alone is still being studied and might be identified in the near future. Although the impregnation of growth factors appears to be capable of rendering such properties, such procedure only shows that the porous bioceramic can serve as a good carrier for growth factors. In addition, it is a challenging task to differentiate whether the osteoinduction is initiated by the implanted material or by a biological mechanism that occurs naturally, especially in injured or defective tissues of the body. These uncertainties have yet to be clarified, and hopefully new discoveries and new research and applicative directions will result. However, the investigation of the combination of factors regarding materials and pore characteristics may be critical for understanding the bone growth phenomena. More studies should be carried out to explore the maintenance of the mechanical properties of ceramics when pores are introduced to them.</p>
<p>Although studies showed that the capabilities of macroporous bioceramics in healing bone defects are obvious, the potential of micro- and mesoporous bioceramics (e.g., HA and TCP) in serving this purpose still require further investigations. Based on reviews,<sup><xref ref-type="bibr" rid="bibr40-0885328211406459">40</xref>,<xref ref-type="bibr" rid="bibr44-0885328211406459">44</xref>,<xref ref-type="bibr" rid="bibr45-0885328211406459">45</xref>,<xref ref-type="bibr" rid="bibr49-0885328211406459">49</xref>,<xref ref-type="bibr" rid="bibr52-0885328211406459">52</xref></sup> micro- and mesopores may not be suitable for osteoconduction due to their extremely small size. Nevertheless, their interactions with the surrounding tissues are worth studying to provide a more complete understanding. However, the synthesis of micro- and mesoporous bioceramics with good pore characteristics (pore volume and size distribution) is agreat challenge, especially for calcium phosphate bioceramics.<sup><xref ref-type="bibr" rid="bibr93-0885328211406459">93</xref><xref ref-type="bibr" rid="bibr94-0885328211406459"/><xref ref-type="bibr" rid="bibr95-0885328211406459"/>–<xref ref-type="bibr" rid="bibr96-0885328211406459">96</xref></sup> Since mesoporous silica and alumina are relatively easier to synthesise, it is believed that successful synthesis depends partially on the simplicity of the chemical structure. Extensive <italic>in vitro </italic>and <italic>in vivo </italic>testing ought to be carried out to understand the potential of micro- and mesoporous bioceramics because they are believed to be a material that is as useful as the high-potential mesoporous silica.</p>
<p>Research on bimodal-pore bioceramics, which possess pores with two distinctive size ranges, is a new direction. Since past studies showed that interconnected porous bioceramics have impressive properties in bone reconstruction, bimodal-pore bioceramics are believed to not only have the same potential in biomedical applications but also exhibit superior mechanical properties. Meanwhile, new porous bioceramics with better mechanical and <italic>in vivo </italic>properties should be developed. The synthesis of porous CHA and FA should also be attempted to study their osteoconductivity. The area of study can also be expanded by embarking on research on the interaction between porous bioceramics and other non-skeletal parts of body to explore new applications.</p>
<p>The osteoconductivity of macroporous bioceramics has been proven to be determined by both the pores and the pore interconnections. The size of the interconnections alone has been shown to affect the osteoconductivity significantly. To enhance the understanding of porous bioceramics, different combinations of pore size and interconnection size can be studied to determine the optimum pore condition required for a porous bioceramic to exhibit superior osteoconduction. Furthermore, the interconnection density can be introduced as a new variable to be studied with the determined optimum combination of pore size and interconnection size. With more knowledge and well-established theories in this area, superior osteoconductivity of various macroporous bioceramics can be achieved more easily.</p>
<p>To date, most of the studies on macroporous bioceramics have revolved around bone implant applications. However, they may also be proficient materials to serve as matrices for animal and plant cell culture applications. Such potential can been seen from their macropores and interconnected pores, which exhibited favourable properties for rapid tissue ingrowth. Thus, more studies ought to be conducted to expand the applications of macroporous bioceramics.</p>
</sec>
<sec id="sec17-0885328211406459" sec-type="conclusions"><title>Conclusion</title>
<p>The presence of pores is usually treated as a defect that leads to unfavourable mechanical properties in conventional ceramics. Although this fact remains applicable for bioceramics, porous structures have opened doors to more advanced development of various types of bioceramics. Macropores and their characteristics areimportant because they can affect the rate oftissue ingrowth and impregnation capacity. However, the research on microporous and mesoporous bioceramics is still young, and, thus, significant discoveries are expected in the future to expand their applications. With a knowledge of both the advantages and disadvantages of pores, bioceramic designers shall maximise the potential of porous bioceramics while retaining the appropriate level of mechanical properties to allow optimal performance of the materials. Some porous ceramics, such as CHA, FA, and titania, are not thoroughly reviewed due to inadequate reports because they are either still in the early stage of synthesis studies or not being tested intensively for biological applications. Thus, there is much room for the study of these classes of materials as potential porous bioceramics.</p>
</sec>
</body>
<back>
<ack><title>Acknowledgements</title>
<p>Financial support from Universiti Sains Malaysia (USM) Fellowship, Fundamental Research Grant Scheme (FRGS) by Malaysian Ministry of Higher Education (MOHE), USM-Research University-Postgraduate Research Grant Scheme (RU-PRGS), and Research Program for Alumni Members (SNRA) 2009 by AUN/SEED-Net (ASEAN-Japan), is gratefully acknowledged.</p></ack>
<ref-list>
<title>References</title>
<ref id="bibr1-0885328211406459"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hench</surname><given-names>LL</given-names></name></person-group>. <article-title>Bioceramics</article-title>. <source>J Am Ceram Soc</source> <year>1998</year>; <volume>81</volume>: <fpage>1705</fpage>–<lpage>1728</lpage>.</citation></ref>
<ref id="bibr2-0885328211406459"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Albee</surname><given-names>FH</given-names></name><name><surname>Morrison</surname><given-names>HR</given-names></name></person-group>. <article-title>Studies in bone growth triple calcium phosphate as a stimulus to osteogenesis</article-title>. <source>Ann Surg</source> <year>1920</year>; <volume>71</volume>: <fpage>32</fpage>–<lpage>39</lpage>.</citation></ref>
<ref id="bibr3-0885328211406459"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Boutin</surname><given-names>P</given-names></name></person-group>. <article-title>Arthroplastie totale de la hanche par prothese en alumina fritte: etude experimentale et premieres applications cliniques</article-title>. <source>Rev Chir Orthop</source> <year>1972</year>; <volume>58</volume>: <fpage>229</fpage>–<lpage>246</lpage>.</citation></ref>
<ref id="bibr4-0885328211406459"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hulbert</surname><given-names>SF</given-names></name><name><surname>Morrison</surname><given-names>SJ</given-names></name><name><surname>Klawitter</surname><given-names>JJ</given-names></name></person-group>. <article-title>Tissue reaction to three ceramics of porous and non-porous structures</article-title>. <source>J Biomed Mater Res</source> <year>1972</year>; <volume>6</volume>: <fpage>347</fpage>–<lpage>374</lpage>.</citation></ref>
<ref id="bibr5-0885328211406459"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hulbert</surname><given-names>SF</given-names></name><name><surname>Young</surname><given-names>FA</given-names></name><name><surname>Mathews</surname><given-names>RS</given-names></name><name><surname>Klawitter</surname><given-names>JJ</given-names></name><name><surname>Talbert</surname><given-names>CD</given-names></name><name><surname>Stelling</surname><given-names>FH</given-names></name></person-group>. <article-title>Potential of ceramic materials as permanently implantable skeletal prostheses</article-title>. <source>J Biomed Mater Res</source> <year>1970</year>; <volume>4</volume>: <fpage>433</fpage>–<lpage>456</lpage>.</citation></ref>
<ref id="bibr6-0885328211406459"><label>6</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>DF</given-names></name></person-group>. <source>The Williams dictionary of Biomaterials</source>. <publisher-loc>Liverpool</publisher-loc>: <publisher-name>Liverpool University Press</publisher-name>, <year>1999</year>.</citation></ref>
<ref id="bibr7-0885328211406459"><label>7</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>Y</given-names></name><name><surname>Yamashita</surname><given-names>K</given-names></name></person-group>. <article-title>Fabrication processes for bioceramics</article-title>. In: <person-group person-group-type="editor"><name><surname>Kokubo</surname><given-names>T</given-names></name></person-group> (ed.) <source>Bioceramics and their clinical applications</source>. <publisher-loc>Cambridge</publisher-loc>: <publisher-name>Woodhead Publishing Limited</publisher-name>, <year>2008</year>, pp. <fpage>28</fpage>–<lpage>52</lpage>.</citation></ref>
<ref id="bibr8-0885328211406459"><label>8</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Shackelford</surname><given-names>JF</given-names></name></person-group>. <source>Advanced ceramics, volume 1: bioceramics</source>. <publisher-loc>Singapore</publisher-loc>: <publisher-name>Gordon and Breach Science Publishers</publisher-name>, <year>2005</year>.</citation></ref>
<ref id="bibr9-0885328211406459"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tamai</surname><given-names>N</given-names></name><name><surname>Myoui</surname><given-names>A</given-names></name><name><surname>Tomita</surname><given-names>T</given-names></name><name><surname>Nakase</surname><given-names>T</given-names></name><name><surname>Tanaka</surname><given-names>J</given-names></name><name><surname>Ochi</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Novel hydroxyapatite ceramics with an interconnective porous structure exhibit superior osteoconduction in vivo</article-title>. <source>J Biomed Mater Res</source> <year>2002</year>; <volume>59</volume>: <fpage>110</fpage>–<lpage>117</lpage>.</citation></ref>
<ref id="bibr10-0885328211406459"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gauthier</surname><given-names>O</given-names></name><name><surname>Bouler</surname><given-names>JM</given-names></name><name><surname>Aguado</surname><given-names>E</given-names></name><name><surname>Pilet</surname><given-names>P</given-names></name><name><surname>Daculsi</surname><given-names>G</given-names></name></person-group>. <article-title>Macroporous biphasic calcium phosphate ceramics influence of macropore diameter and macroporosity percentage on bone ingrowth</article-title>. <source>Biomaterials</source> <year>1998</year>; <volume>19</volume>: <fpage>133</fpage>–<lpage>139</lpage>.</citation></ref>
<ref id="bibr11-0885328211406459"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yamasaki</surname><given-names>H</given-names></name><name><surname>Sakai</surname><given-names>H</given-names></name></person-group>. <article-title>Osteogenic response to porous hydroxyapatite ceramics under the skin of dogs</article-title>. <source>Biomaterials</source> <year>1992</year>; <volume>13</volume>: <fpage>308</fpage>–<lpage>312</lpage>.</citation></ref>
<ref id="bibr12-0885328211406459"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yunoki</surname><given-names>S</given-names></name><name><surname>Ikoma</surname><given-names>T</given-names></name><name><surname>Tsuchiya</surname><given-names>A</given-names></name><name><surname>Monkawa</surname><given-names>A</given-names></name><name><surname>Ohta</surname><given-names>K</given-names></name><name><surname>Sotome</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Fabrication and mechanical and tissue ingrowth properties of unidirectionally porous hydroxyapatite/collagen composite</article-title>. <source>J Biomed Mater Res</source> <year>2007</year>; <volume>80B</volume>: <fpage>166</fpage>–<lpage>173</lpage>.</citation></ref>
<ref id="bibr13-0885328211406459"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>H</given-names></name><name><surname>De Groot</surname><given-names>K</given-names></name></person-group>. <article-title>Calcium phosphate biomaterials an overview</article-title>. In: <person-group person-group-type="editor"><name><surname>Reis</surname><given-names>RL</given-names></name><name><surname>Weiner</surname><given-names>S</given-names></name></person-group> (eds) <source>Learning from nature how to design new implantable biomaterials</source>. <publisher-loc>Netherlands</publisher-loc>: <publisher-name>Kluwer Academic Publishers</publisher-name>, <year>2004</year>, pp. <fpage>37</fpage>–<lpage>57</lpage>.</citation></ref>
<ref id="bibr14-0885328211406459"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dorozhkin</surname><given-names>SV</given-names></name></person-group>. <article-title>Bioceramics of calcium orthophosphates</article-title>. <source>Biomaterials</source> <year>2010</year>; <volume>31</volume>: <fpage>1465</fpage>–<lpage>1485</lpage>.</citation></ref>
<ref id="bibr15-0885328211406459"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sing</surname><given-names>KSW</given-names></name><name><surname>Everett</surname><given-names>DH</given-names></name><name><surname>Haul</surname><given-names>RAW</given-names></name><name><surname>Moscou</surname><given-names>L</given-names></name><name><surname>Pierotti</surname><given-names>RA</given-names></name><name><surname>Rouquerol</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Reporting physisorption data for gas/solid systems with special reference to the determination of surface area and porosity</article-title>. <source>Pure Appl Chem</source> <year>1985</year>; <volume>57</volume>: <fpage>603</fpage>–<lpage>619</lpage>.</citation></ref>
<ref id="bibr16-0885328211406459"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Holmes</surname><given-names>RE</given-names></name><name><surname>Bucholz</surname><given-names>RW</given-names></name><name><surname>Mooney</surname><given-names>V</given-names></name></person-group>. <article-title>Porous hydroxyapatite as a bone graft substitute in diaphyseal defects a histometric study</article-title>. <source>J Orthop Res</source> <year>1987</year>; <volume>5</volume>: <fpage>114</fpage>–<lpage>121</lpage>.</citation></ref>
<ref id="bibr17-0885328211406459"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Holmes</surname><given-names>RE</given-names></name><name><surname>Bucholz</surname><given-names>RW</given-names></name><name><surname>Mooney</surname><given-names>V</given-names></name></person-group>. <article-title>Porous hydroxyapatite as a bone graft substitute in metaphyseal defects a histometric study</article-title>. <source>J Bone Joint Surg Am</source> <year>1986</year>; <volume>68</volume>: <fpage>904</fpage>–<lpage>911</lpage>.</citation></ref>
<ref id="bibr18-0885328211406459"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shimazaki</surname><given-names>K</given-names></name><name><surname>Mooney</surname><given-names>V</given-names></name></person-group>. <article-title>Comparative study of porous hydroxyapatite and tricalcium phosphate as bone substitute</article-title>. <source>J Orthop Res</source> <year>1985</year>; <volume>3</volume>: <fpage>301</fpage>–<lpage>310</lpage>.</citation></ref>
<ref id="bibr19-0885328211406459"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Albrektsson</surname><given-names>T</given-names></name><name><surname>Johansson</surname><given-names>C</given-names></name></person-group>. <article-title>Osteoinduction, ssteoconduction and ssseointegration</article-title>. <source>Eur Spine J</source> <year>2001</year>; <volume>10</volume>: <fpage>S96</fpage>–<lpage>S101</lpage>.</citation></ref>
<ref id="bibr20-0885328211406459"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Uchida</surname><given-names>A</given-names></name><name><surname>Shinto</surname><given-names>Y</given-names></name><name><surname>Araki</surname><given-names>N</given-names></name><name><surname>Ono</surname><given-names>K</given-names></name></person-group>. <article-title>Slow release of anticancer drugs from porous calcium hydroxyapatite ceramic</article-title>. <source>J Orthop Res</source> <year>1992</year>; <volume>10</volume>: <fpage>440</fpage>–<lpage>445</lpage>.</citation></ref>
<ref id="bibr21-0885328211406459"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>MY</given-names></name><name><surname>Zhu</surname><given-names>YJ</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Cao</surname><given-names>SW</given-names></name></person-group>. <article-title>Nanostructured porous hollow ellipsoidal capsules of hydroxyapatite and calcium silicate: preparation and application in drug delivery</article-title>. <source>J Mater Chem</source> <year>2008</year>; <volume>18</volume>: <fpage>2722</fpage>–<lpage>2727</lpage>.</citation></ref>
<ref id="bibr22-0885328211406459"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Galbusera</surname><given-names>F</given-names></name><name><surname>Bertolazzi</surname><given-names>L</given-names></name><name><surname>Balossino</surname><given-names>R</given-names></name><name><surname>Dubini</surname><given-names>G</given-names></name></person-group>. <article-title>Combined computational study of mechanical behaviour and drug delivery from a porous, hydroxyaptite-based bone graft</article-title>. <source>Biomech Model Mechanobiol</source> <year>2009</year>; <volume>8</volume>: <fpage>209</fpage>–<lpage>216</lpage>.</citation></ref>
<ref id="bibr23-0885328211406459"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Silverman</surname><given-names>LD</given-names></name><name><surname>Lukashova</surname><given-names>L</given-names></name><name><surname>Herman</surname><given-names>OT</given-names></name><name><surname>Lane</surname><given-names>JM</given-names></name><name><surname>Boskey</surname><given-names>AL</given-names></name></person-group>. <article-title>Release of gentamicin from a tricalcium phosphate bone implant</article-title>. <source>J Orthop Res</source> <year>2007</year>; <volume>25</volume>: <fpage>23</fpage>–<lpage>29</lpage>.</citation></ref>
<ref id="bibr24-0885328211406459"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Slowing</surname><given-names>II</given-names></name><name><surname>Escoto</surname><given-names>JLV</given-names></name><name><surname>Wu</surname><given-names>CW</given-names></name><name><surname>Lin</surname><given-names>VSY</given-names></name></person-group>. <article-title>Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers</article-title>. <source>Adv Drug Del Rev</source> <year>2008</year>; <volume>60</volume>: <fpage>1278</fpage>–<lpage>1288</lpage>.</citation></ref>
<ref id="bibr25-0885328211406459"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Yan</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Tang</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Mesoporous bioactive glasses for controlled drug release</article-title>. <source>Microporous Mesoporous Mater</source> <year>2008</year>; <volume>109</volume>: <fpage>210</fpage>–<lpage>215</lpage>.</citation></ref>
<ref id="bibr26-0885328211406459"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Kaskel</surname><given-names>S</given-names></name></person-group>. <article-title>Comparison of the in vitro bioactivity and drug release property of mesoporous bioactive glasses (MBGs) and bioactive glasses (BGs) scaffolds</article-title>. <source>Microporous Mesoporous Mater</source> <year>2009</year>; <volume>118</volume>: <fpage>176</fpage>–<lpage>182</lpage>.</citation></ref>
<ref id="bibr27-0885328211406459"><label>27</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Hench</surname><given-names>LL</given-names></name><name><surname>Wilson</surname><given-names>J</given-names></name></person-group>. <source>An introduction to bioceramics</source>. <publisher-loc>Singapore</publisher-loc>: <publisher-name>World Scientific</publisher-name>, <year>1993</year>.</citation></ref>
<ref id="bibr28-0885328211406459"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Den Boer</surname><given-names>FC</given-names></name><name><surname>Wippermann</surname><given-names>BW</given-names></name><name><surname>Blokhuis</surname><given-names>TJ</given-names></name><name><surname>Patka</surname><given-names>P</given-names></name><name><surname>Bakker</surname><given-names>FC</given-names></name><name><surname>Haarman</surname><given-names>HJTM</given-names></name></person-group>. <article-title>Healing of segmental bone defects with granular porous hydroxyapatite augmented with recombinant human osteogenic protein-1 or autologous bone marrow</article-title>. <source>J Orthop Res</source> <year>2003</year>; <volume>21</volume>: <fpage>521</fpage>–<lpage>528</lpage>.</citation></ref>
<ref id="bibr29-0885328211406459"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>H</given-names></name><name><surname>Kurashina</surname><given-names>K</given-names></name><name><surname>De Bruijn</surname><given-names>JD</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>De Groot</surname><given-names>K</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name></person-group>. <article-title>A preliminary study on osteoinduction of two kinds of calcium phosphate ceramics</article-title>. <source>Biomaterials</source> <year>1999</year>; <volume>20</volume>: <fpage>1799</fpage>–<lpage>1806</lpage>.</citation></ref>
<ref id="bibr30-0885328211406459"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bodde</surname><given-names>EWH</given-names></name><name><surname>Wolke</surname><given-names>JGC</given-names></name><name><surname>Rick</surname><given-names>SZK</given-names></name><name><surname>Jansen</surname><given-names>JA</given-names></name></person-group>. <article-title>Bone regeneration of porous β-tricalcium phosphate (Conduit™ TCP) and of biphasic calcium phosphate ceramic (Biosel®) in trabecular defects in sheep</article-title>. <source>JBiomed Mater Res</source> <year>2007</year>; <volume>82A</volume>: <fpage>711</fpage>–<lpage>722</lpage>.</citation></ref>
<ref id="bibr31-0885328211406459"><label>31</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>D</given-names></name><name><surname>Wen</surname><given-names>X</given-names></name></person-group>. <article-title>Bioactive ceramics structure synthesis and mechanical properties</article-title>. In: <person-group person-group-type="editor"><name><surname>Shi</surname><given-names>D</given-names></name></person-group> (ed.) <source>Introduction to biomaterials</source>. <publisher-loc>China</publisher-loc>: <publisher-name>Tsinghua University Press, Singapore: World Scientific Publishing</publisher-name>, <year>2006</year>, pp. <fpage>25</fpage>–<lpage>25</lpage>.</citation></ref>
<ref id="bibr32-0885328211406459"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rey</surname><given-names>C</given-names></name><name><surname>Combes</surname><given-names>C</given-names></name><name><surname>Drouet</surname><given-names>C</given-names></name><name><surname>Somrani</surname><given-names>S</given-names></name></person-group>. <article-title>Tricalcium phosphate-based ceramics</article-title>. In: <person-group person-group-type="editor"><name><surname>Kokubo</surname><given-names>T</given-names></name></person-group> (ed.) <source>Bioceramics and their clinical applications</source>. <publisher-loc>Cambridge</publisher-loc>: <publisher-name>Woodhead Publishing Limited</publisher-name>, <year>2008</year>, pp. <fpage>326</fpage>–<lpage>355</lpage>.</citation></ref>
<ref id="bibr33-0885328211406459"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dos Santos</surname><given-names>LA</given-names></name><name><surname>Carrodeguas</surname><given-names>RG</given-names></name><name><surname>Rogero</surname><given-names>SO</given-names></name><name><surname>Higa</surname><given-names>OZ</given-names></name><name><surname>Boschi</surname><given-names>AO</given-names></name><name><surname>De Arruda</surname><given-names>ACF</given-names></name></person-group>. <article-title>α-tricalcium phosphate cement “in vitro” cytotoxicity</article-title>. <source>Biomaterials</source> <year>2002</year>; <volume>23</volume>: <fpage>2035</fpage>–<lpage>2042</lpage>.</citation></ref>
<ref id="bibr34-0885328211406459"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wakae</surname><given-names>H</given-names></name><name><surname>Takeuchi</surname><given-names>A</given-names></name><name><surname>Udoh</surname><given-names>K</given-names></name><name><surname>Matsuya</surname><given-names>S</given-names></name><name><surname>Munar</surname><given-names>ML</given-names></name><name><surname>LeGeros</surname><given-names>RZ</given-names></name><etal/></person-group>. <article-title>Fabrication of macroporous carbonate apatite foam by hydrothermal conversion of α-tricalcium phosphate in carbonate solutions</article-title>. <source>J Biomed Mater Res</source> <year>2008</year>; <volume>87A</volume>: <fpage>957</fpage>–<lpage>963</lpage>.</citation></ref>
<ref id="bibr35-0885328211406459"><label>35</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Park</surname><given-names>J</given-names></name></person-group>. <source>Bioceramics properties, characterization, and applications</source>. <publisher-loc>New York</publisher-loc>: <publisher-name>Springer Science+Business Media</publisher-name>, <year>2008</year>.</citation></ref>
<ref id="bibr36-0885328211406459"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Asazuma</surname><given-names>T</given-names></name><name><surname>Masuoka</surname><given-names>K</given-names></name><name><surname>Motosuneya</surname><given-names>T</given-names></name><name><surname>Tsuji</surname><given-names>T</given-names></name><name><surname>Yasuoka</surname><given-names>H</given-names></name><name><surname>Fujikawa</surname><given-names>K</given-names></name></person-group>. <article-title>Posterior lumbar interbody fusion using dense hydroxyapatite blocks and autogenous iliac bone</article-title>. <source>J Spinal Disord Tech</source> <year>2005</year>; <volume>18</volume>: <fpage>41</fpage>–<lpage>47</lpage>.</citation></ref>
<ref id="bibr37-0885328211406459"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mangano</surname><given-names>C</given-names></name><name><surname>Piattelli</surname><given-names>A</given-names></name><name><surname>Perrotti</surname><given-names>V</given-names></name><name><surname>Iezzi</surname><given-names>G</given-names></name></person-group>. <article-title>Dense hydroxyapatite inserted into postextraction sockets a histologic and histomorphometric 20-year case report</article-title>. <source>JPeriodontol</source> <year>2008</year>; <volume>79</volume>: <fpage>929</fpage>–<lpage>933</lpage>.</citation></ref>
<ref id="bibr38-0885328211406459"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Layman</surname><given-names>DL</given-names></name><name><surname>Ardoin</surname><given-names>RC</given-names></name></person-group>. <article-title>An in vitro system for studying osteointegration of dental implants utilizing cells grown on dense hydroxyapatite disks</article-title>. <source>J Biomed Mater Res</source> <year>1998</year>; <volume>40</volume>: <fpage>282</fpage>–<lpage>290</lpage>.</citation></ref>
<ref id="bibr39-0885328211406459"><label>39</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>QZ</given-names></name><name><surname>Bretcanu</surname><given-names>O</given-names></name><name><surname>Boccaccini</surname><given-names>AR</given-names></name></person-group>. <article-title>Inorganic and composite bioactive scaffolds for bone tissue engineering</article-title>. In: <person-group person-group-type="editor"><name><surname>Chu</surname><given-names>PK</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name></person-group> (eds) <source>Biomaterials fabrication and processing handbook</source>. <publisher-loc>Boca Raton</publisher-loc>: <publisher-name>CRC Press</publisher-name>, <year>2008</year>, pp. <fpage>3</fpage>–<lpage>43</lpage>.</citation></ref>
<ref id="bibr40-0885328211406459"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>BS</given-names></name><name><surname>Lee</surname><given-names>CK</given-names></name><name><surname>Hong</surname><given-names>KS</given-names></name><name><surname>Youn</surname><given-names>HJ</given-names></name><name><surname>Ryu</surname><given-names>HS</given-names></name><name><surname>Chung</surname><given-names>SS</given-names></name><etal/></person-group>. <article-title>Osteoconduction at porous hydroxyapatite with various pore configurations</article-title>. <source>Biomaterials</source> <year>2000</year>; <volume>21</volume>: <fpage>1291</fpage>–<lpage>1298</lpage>.</citation></ref>
<ref id="bibr41-0885328211406459"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vuola</surname><given-names>J</given-names></name><name><surname>Taurio</surname><given-names>R</given-names></name><name><surname>Goransson</surname><given-names>H</given-names></name><name><surname>Seljavaara</surname><given-names>SA</given-names></name></person-group>. <article-title>Compressive strength of calcium carbonate and hydroxyapatite implants after bone-marrow-induced osteogenesis</article-title>. <source>Biomaterials</source> <year>1998</year>; <volume>19</volume>: <fpage>223</fpage>–<lpage>227</lpage>.</citation></ref>
<ref id="bibr42-0885328211406459"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hench</surname><given-names>LL</given-names></name></person-group>. <article-title>Bioceramics from concept to clinic</article-title>. <source>J Am Ceram Soc</source> <year>1991</year>; <volume>74</volume>: <fpage>1487</fpage>–<lpage>1510</lpage>.</citation></ref>
<ref id="bibr43-0885328211406459"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Omae</surname><given-names>H</given-names></name><name><surname>Mochizuki</surname><given-names>Y</given-names></name><name><surname>Yokoya</surname><given-names>S</given-names></name><name><surname>Adachi</surname><given-names>N</given-names></name><name><surname>Ochi</surname><given-names>M</given-names></name></person-group>. <article-title>Effects of interconnecting porous structure of hydroxyapatite ceramics on interface between grafted tendon and ceramics</article-title>. <source>J Biomed Mater Res</source> <year>2006</year>; <volume>79A</volume>: <fpage>329</fpage>–<lpage>337</lpage>.</citation></ref>
<ref id="bibr44-0885328211406459"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Andrade</surname><given-names>JCT</given-names></name><name><surname>Camilli</surname><given-names>JA</given-names></name><name><surname>Kawachi</surname><given-names>EY</given-names></name><name><surname>Bertran</surname><given-names>CA</given-names></name></person-group>. <article-title>Behavior of dense and porous hydroxyapatite implants and tissue response in rat femoral defects</article-title>. <source>J Biomed Mater Res</source> <year>2002</year>; <volume>62A</volume>: <fpage>30</fpage>–<lpage>36</lpage>.</citation></ref>
<ref id="bibr45-0885328211406459"><label>45</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kuhne</surname><given-names>JH</given-names></name><name><surname>Bartl</surname><given-names>R</given-names></name><name><surname>Frisch</surname><given-names>B</given-names></name><name><surname>Hammer</surname><given-names>C</given-names></name><name><surname>Jansson</surname><given-names>V</given-names></name><name><surname>Zimmer</surname><given-names>M</given-names></name></person-group>. <article-title>Bone formation in coralline hydroxyapatite effects of pore size studied in rabbits</article-title>. <source>Acta Orthop Scand</source> <year>1994</year>; <volume>65</volume>: <fpage>246</fpage>–<lpage>252</lpage>.</citation></ref>
<ref id="bibr46-0885328211406459"><label>46</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hing</surname><given-names>KA</given-names></name><name><surname>Best</surname><given-names>SM</given-names></name><name><surname>Tanner</surname><given-names>KE</given-names></name><name><surname>Bonfield</surname><given-names>W</given-names></name><name><surname>Revell</surname><given-names>PA</given-names></name></person-group>. <article-title>Mediation of bone ingrowth in porous hydroxyapatite bone graft substitutes</article-title>. <source>J Biomed Mater Res</source> <year>2004</year>; <volume>68A</volume>: <fpage>187</fpage>–<lpage>200</lpage>.</citation></ref>
<ref id="bibr47-0885328211406459"><label>47</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ayers</surname><given-names>RA</given-names></name><name><surname>Wolford</surname><given-names>LM</given-names></name><name><surname>Bateman</surname><given-names>TA</given-names></name><name><surname>Ferguson</surname><given-names>VL</given-names></name><name><surname>Simske</surname><given-names>SJ</given-names></name></person-group>. <article-title>Quantification of bone ingrowth into porous block hydroxyapatite in humans</article-title>. <source>J Biomed Mater Res</source> <year>1999</year>; <volume>47</volume>: <fpage>54</fpage>–<lpage>59</lpage>.</citation></ref>
<ref id="bibr48-0885328211406459"><label>48</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ryu</surname><given-names>HS</given-names></name><name><surname>Kim</surname><given-names>SJ</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Hong</surname><given-names>KS</given-names></name><name><surname>Chang</surname><given-names>BS</given-names></name><etal/></person-group>. <article-title>Fabrication of 1-dimensional porous hydroxyapatite and evaluation of its osteoconductivity</article-title>. <source>J Mater Sci Mater Med</source> <year>2004</year>; <volume>15</volume>: <fpage>267</fpage>–<lpage>273</lpage>.</citation></ref>
<ref id="bibr49-0885328211406459"><label>49</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>XJ</given-names></name><name><surname>Flautre</surname><given-names>B</given-names></name><name><surname>AnselmeK, Hardouin</surname><given-names>P</given-names></name><name><surname>Gallur</surname><given-names>A</given-names></name><name><surname>Descamps</surname><given-names>M</given-names></name><name><surname>Thierry</surname><given-names>B</given-names></name></person-group>. <article-title>Role of interconnections in porous bioceramics on bone recolonization in vitro and in vivo</article-title>. <source>J Mater Sci Mater Med</source> <year>1999</year>; <volume>10</volume>: <fpage>111</fpage>–<lpage>120</lpage>.</citation></ref>
<ref id="bibr50-0885328211406459"><label>50</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hutmacher</surname><given-names>DW</given-names></name></person-group>. <article-title>Scaffolds in tissue engineering bone and cartilage</article-title>. <source>Biomaterials</source> <year>2000</year>; <volume>21</volume>: <fpage>2529</fpage>–<lpage>2543</lpage>.</citation></ref>
<ref id="bibr51-0885328211406459"><label>51</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hing</surname><given-names>KA</given-names></name><name><surname>Best</surname><given-names>SM</given-names></name><name><surname>Tanner</surname><given-names>KE</given-names></name><name><surname>Bonfield</surname><given-names>W</given-names></name><name><surname>Revell</surname><given-names>PA</given-names></name></person-group>. <article-title>Quantification of bone ingrowth within bone-derived porous hydroxyapatite implants of varying density</article-title>. <source>J Mater Sci Mater Med</source> <year>1999</year>; <volume>10</volume>: <fpage>663</fpage>–<lpage>670</lpage>.</citation></ref>
<ref id="bibr52-0885328211406459"><label>52</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kokubun</surname><given-names>S</given-names></name><name><surname>Kashimoto</surname><given-names>O</given-names></name><name><surname>Tanaka</surname><given-names>Y</given-names></name></person-group>. <article-title>Histological verification of bone bonding and ingrowth into porous hydroxyapatite spinous process spacer for cervical laminoplasty</article-title>. <source>Tohoku J Exp Med</source> <year>1994</year>; <volume>173</volume>: <fpage>337</fpage>–<lpage>344</lpage>.</citation></ref>
<ref id="bibr53-0885328211406459"><label>53</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Flautre</surname><given-names>B</given-names></name><name><surname>Descamps</surname><given-names>M</given-names></name><name><surname>Delecourt</surname><given-names>C</given-names></name><name><surname>Blary</surname><given-names>MC</given-names></name><name><surname>Hardouin</surname><given-names>P</given-names></name></person-group>. <article-title>Porous hydroxyapatite ceramic for bone replacement: role of the pores and interconnections – experimental study in the rabbit</article-title>. <source>J Mater Sci Mater Med</source> <year>2001</year>; <volume>12</volume>: <fpage>679</fpage>–<lpage>682</lpage>.</citation></ref>
<ref id="bibr54-0885328211406459"><label>54</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ripamonti</surname><given-names>U</given-names></name></person-group>. <article-title>Osteoinduction in porous hydroxyapatite implanted in heterotopic sites of different animal models</article-title>. <source>Biomaterials</source> <year>1996</year>; <volume>17</volume>: <fpage>31</fpage>–<lpage>35</lpage>.</citation></ref>
<ref id="bibr55-0885328211406459"><label>55</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Urist</surname><given-names>MR</given-names></name><name><surname>Huo</surname><given-names>YK</given-names></name><name><surname>Brownell</surname><given-names>AG</given-names></name><name><surname>Hohl</surname><given-names>WM</given-names></name><name><surname>Buyske</surname><given-names>J</given-names></name><name><surname>Lietze</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Purification of bovine bone morphogenetic protein by hydroxyapatite chromatography</article-title>. <source>Proc Natl Acad Sci</source> <year>1984</year>; <volume>81</volume>: <fpage>371</fpage>–<lpage>375</lpage>.</citation></ref>
<ref id="bibr56-0885328211406459"><label>56</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>X</given-names></name><name><surname>Lee</surname><given-names>KM</given-names></name><name><surname>Law</surname><given-names>LP</given-names></name><name><surname>Chow</surname><given-names>HKD</given-names></name><name><surname>Rosier</surname><given-names>R</given-names></name><name><surname>Cheng</surname><given-names>CYJ</given-names></name></person-group>. <article-title>Recombinant human bone morphogenetic protein-4 (rhBMP-4) enhanced posterior spinal fusion without decortication</article-title>. <source>J Orthop Res</source> <year>2002</year>; <volume>20</volume>: <fpage>740</fpage>–<lpage>746</lpage>.</citation></ref>
<ref id="bibr57-0885328211406459"><label>57</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>EA</given-names></name><name><surname>Rosen</surname><given-names>V</given-names></name><name><surname>D'Alessandro</surname><given-names>JS</given-names></name><name><surname>Bauduy</surname><given-names>M</given-names></name><name><surname>Cordes</surname><given-names>P</given-names></name><name><surname>Harada</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Recombinant human bone morphogenetic protein induces bone formation</article-title>. <source>Proc Natl Acad Sci</source> <year>1990</year>; <volume>87</volume>: <fpage>2220</fpage>–<lpage>2224</lpage>.</citation></ref>
<ref id="bibr58-0885328211406459"><label>58</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ito</surname><given-names>Y</given-names></name><name><surname>Tanaka</surname><given-names>N</given-names></name><name><surname>Fujimoto</surname><given-names>Y</given-names></name><name><surname>Yasunaga</surname><given-names>Y</given-names></name><name><surname>Ishida</surname><given-names>O</given-names></name><name><surname>Agung</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Bone formation using novel interconnected porous calcium hydroxyapatite ceramic hybridized with cultured marrow stromal stem cells derived from green rat</article-title>. <source>J Biomed Mater Res</source> <year>2004</year>; <volume>69A</volume>: <fpage>454</fpage>–<lpage>461</lpage>.</citation></ref>
<ref id="bibr59-0885328211406459"><label>59</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nakasa</surname><given-names>T</given-names></name><name><surname>Ishida</surname><given-names>O</given-names></name><name><surname>Sunagawa</surname><given-names>T</given-names></name><name><surname>Nakamae</surname><given-names>A</given-names></name><name><surname>Yasunaga</surname><given-names>Y</given-names></name><name><surname>Agung</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Prefabrication of vascularized bone graft using a combination of fibroblast growth factor-2 and vascular bundle implantation into a novel interconnected porous calcium hydroxyapatite ceramic</article-title>. <source>J Biomed Mater Res</source> <year>2005</year>; <volume>75A</volume>: <fpage>350</fpage>–<lpage>355</lpage>.</citation></ref>
<ref id="bibr60-0885328211406459"><label>60</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Knabe</surname><given-names>C</given-names></name><name><surname>Koch</surname><given-names>C</given-names></name><name><surname>Rack</surname><given-names>A</given-names></name><name><surname>Stiller</surname><given-names>M</given-names></name></person-group>. <article-title>Effect of β-tricalcium phosphate particles with varying porosity on osteogenesis after sinus floor augmentation in humans</article-title>. <source>Biomaterials</source> <year>2008</year>; <volume>29</volume>: <fpage>2249</fpage>–<lpage>2258</lpage>.</citation></ref>
<ref id="bibr61-0885328211406459"><label>61</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>QX</given-names></name><name><surname>Zhu</surname><given-names>TB</given-names></name><name><surname>Du</surname><given-names>JY</given-names></name><name><surname>Hong</surname><given-names>GX</given-names></name><name><surname>Li</surname><given-names>SP</given-names></name><name><surname>Yan</surname><given-names>YH</given-names></name><etal/></person-group>. <article-title>Artificial bone of porous tricalcium phosphate ceramics and its preliminary clinical application</article-title>. <source>J Tongji Med Univ</source> <year>1992</year>; <volume>12</volume>: <fpage>173</fpage>–<lpage>178</lpage>.</citation></ref>
<ref id="bibr62-0885328211406459"><label>62</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ogose</surname><given-names>A</given-names></name><name><surname>Hotta</surname><given-names>T</given-names></name><name><surname>Hatano</surname><given-names>H</given-names></name><name><surname>Kawashima</surname><given-names>H</given-names></name><name><surname>Tokunaga</surname><given-names>K</given-names></name><name><surname>Endo</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Histological examination of β-tricalcium phosphate graft in human femur</article-title>. <source>J Biomed Mater Res</source> <year>2002</year>; <volume>63B</volume>: <fpage>601</fpage>–<lpage>604</lpage>.</citation></ref>
<ref id="bibr63-0885328211406459"><label>63</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zerbo</surname><given-names>IR</given-names></name><name><surname>Bronckers</surname><given-names>ALJJ</given-names></name><name><surname>De Lange</surname><given-names>G</given-names></name><name><surname>Van Beek</surname><given-names>GJ</given-names></name><name><surname>Burger</surname><given-names>EH</given-names></name></person-group>. <article-title>Histology of human alveolar bone regeneration with a porous tricalcium phosphate</article-title>. <source>Clin Oral Impl Res</source> <year>2001</year>; <volume>12</volume>: <fpage>379</fpage>–<lpage>384</lpage>.</citation></ref>
<ref id="bibr64-0885328211406459"><label>64</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zerbo</surname><given-names>IR</given-names></name><name><surname>Bronckers</surname><given-names>ALJJ</given-names></name><name><surname>De Lange</surname><given-names>G</given-names></name><name><surname>Burger</surname><given-names>EH</given-names></name></person-group>. <article-title>Localisation of osteogenic and osteoclastic cells in porous β-tricalcium phosphate particles used for human maxilarry sinus floor elevation</article-title>. <source>Biomaterials</source> <year>2005</year>; <volume>26</volume>: <fpage>1445</fpage>–<lpage>1451</lpage>.</citation></ref>
<ref id="bibr65-0885328211406459"><label>65</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zerbo</surname><given-names>IR</given-names></name><name><surname>Zijderveld</surname><given-names>SA</given-names></name><name><surname>De Boer</surname><given-names>A</given-names></name><name><surname>Bronckers</surname><given-names>ALJJ</given-names></name><name><surname>De Lange</surname><given-names>G</given-names></name><name><surname>Ten Bruggenkate</surname><given-names>CM</given-names></name><etal/></person-group>. <article-title>Histomorephometry of human sinus floor augmentation using a porous β-tricalcium phosphate a prospective study</article-title>. <source>Clin Oral Impl Res</source> <year>2004</year>; <volume>15</volume>: <fpage>724</fpage>–<lpage>732</lpage>.</citation></ref>
<ref id="bibr66-0885328211406459"><label>66</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Laffargue</surname><given-names>PH</given-names></name><name><surname>Hildebrand</surname><given-names>HF</given-names></name><name><surname>Rtaimate</surname><given-names>M</given-names></name><name><surname>Frayssinet</surname><given-names>P</given-names></name><name><surname>Amoureux</surname><given-names>JP</given-names></name><name><surname>Marchandise</surname><given-names>X</given-names></name></person-group>. <article-title>Evaluation of human recombinant bone morphogenetic protein-2-loaded tricalcium phosphate implants in rabbits’ bone defects</article-title>. <source>Bone</source> <year>1999</year>; <volume>25</volume>: <fpage>55S</fpage>–<lpage>58S</lpage>.</citation></ref>
<ref id="bibr67-0885328211406459"><label>67</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Matsushita</surname><given-names>N</given-names></name><name><surname>Terai</surname><given-names>H</given-names></name><name><surname>Okada</surname><given-names>T</given-names></name><name><surname>Nozaki</surname><given-names>K</given-names></name><name><surname>Inoue</surname><given-names>H</given-names></name><name><surname>Miyamoto</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>A new bone-inducing biodegradable porous β-tricalcium phosphate</article-title>. <source>J Biomed Mater Res</source> <year>2004</year>; <volume>70A</volume>: <fpage>450</fpage>–<lpage>458</lpage>.</citation></ref>
<ref id="bibr68-0885328211406459"><label>68</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>G</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Oh</surname><given-names>S</given-names></name><name><surname>Ong</surname><given-names>JL</given-names></name><name><surname>Zheng</surname><given-names>C</given-names></name><name><surname>Ran</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Ectopic osteoinduction and early degradation of recombinant human bone morphogenetic protein-2-loaded porous β-tricalcium phosphate in mice</article-title>. <source>Biomaterials</source> <year>2005</year>; <volume>26</volume>: <fpage>4265</fpage>–<lpage>4271</lpage>.</citation></ref>
<ref id="bibr69-0885328211406459"><label>69</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hoshino</surname><given-names>M</given-names></name><name><surname>Egi</surname><given-names>T</given-names></name><name><surname>Terai</surname><given-names>H</given-names></name><name><surname>Namikawa</surname><given-names>T</given-names></name><name><surname>Takaoka</surname><given-names>K</given-names></name></person-group>. <article-title>Repair of long intercalated rib defects using porous beta-tricalcium phosphate cylinders containing recombinant human bone morphogenetic protein-2 in dogs</article-title>. <source>Biomaterials</source> <year>2006</year>; <volume>27</volume>: <fpage>4934</fpage>–<lpage>4940</lpage>.</citation></ref>
<ref id="bibr70-0885328211406459"><label>70</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Laffargue</surname><given-names>P</given-names></name><name><surname>Fialdes</surname><given-names>P</given-names></name><name><surname>Frayssinet</surname><given-names>P</given-names></name><name><surname>Rtaimate</surname><given-names>M</given-names></name><name><surname>Hildebrand</surname><given-names>HF</given-names></name><name><surname>Marchandise</surname><given-names>X</given-names></name></person-group>. <article-title>Adsorption and release of insulin-like growth factor-I on porous tricalcium phosphate implant</article-title>. <source>J Biomed Mater Res</source> <year>2000</year>; <volume>49</volume>: <fpage>415</fpage>–<lpage>421</lpage>.</citation></ref>
<ref id="bibr71-0885328211406459"><label>71</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Steffen</surname><given-names>T</given-names></name><name><surname>Stoll</surname><given-names>T</given-names></name><name><surname>Arvinte</surname><given-names>T</given-names></name><name><surname>Schenk</surname><given-names>RK</given-names></name></person-group>. <article-title>Porous tricalcium phosphate and transforming growth factor used for anterior spine surgery</article-title>. <source>Eur Spine J</source> <year>2001</year>; <volume>10</volume>: <fpage>S132</fpage>–<lpage>S140</lpage>.</citation></ref>
<ref id="bibr72-0885328211406459"><label>72</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>J</given-names></name><name><surname>Cui</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>WJ</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name></person-group>. <article-title>Repair of canine mandibular bone defects with bone marrow stromal cells and porous β-tricalcium phosphate</article-title>. <source>Biomaterials</source> <year>2007</year>; <volume>28</volume>: <fpage>1005</fpage>–<lpage>1013</lpage>.</citation></ref>
<ref id="bibr73-0885328211406459"><label>73</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gan</surname><given-names>Y</given-names></name><name><surname>Dai</surname><given-names>K</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Tang</surname><given-names>T</given-names></name><name><surname>Zhu</surname><given-names>Z</given-names></name><name><surname>Lu</surname><given-names>J</given-names></name></person-group>. <article-title>The clinical use of enriched bone marrow stem cells combined with porous beta-tricalcium phosphate in posterior spinal fusion</article-title>. <source>Biomaterials</source> <year>2008</year>; <volume>29</volume>: <fpage>3973</fpage>–<lpage>3982</lpage>.</citation></ref>
<ref id="bibr74-0885328211406459"><label>74</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sohier</surname><given-names>J</given-names></name><name><surname>Daculsi</surname><given-names>G</given-names></name><name><surname>Sourice</surname><given-names>S</given-names></name><name><surname>De Groot</surname><given-names>K</given-names></name><name><surname>Layrolle</surname><given-names>P</given-names></name></person-group>. <article-title>Porous beta tricalcium phosphate scaffolds used as a BMP-2 delivery system for bone tissue engineering</article-title>. <source>J Biomed Mater Res</source> <year>2009</year>; <volume>92A</volume>: <fpage>1105</fpage>–<lpage>1114</lpage>.</citation></ref>
<ref id="bibr75-0885328211406459"><label>75</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tamura</surname><given-names>K</given-names></name><name><surname>Sato</surname><given-names>S</given-names></name><name><surname>Kishida</surname><given-names>M</given-names></name><name><surname>Asano</surname><given-names>S</given-names></name><name><surname>Murai</surname><given-names>M</given-names></name><name><surname>Ito</surname><given-names>K</given-names></name></person-group>. <article-title>The use of porous β-tricalcium phosphate blocks with platelet-rich plasma as an onlay bone graft biomaterial</article-title>. <source>J Periodontol</source> <year>2007</year>; <volume>78</volume>: <fpage>315</fpage>–<lpage>321</lpage>.</citation></ref>
<ref id="bibr76-0885328211406459"><label>76</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ohgushi</surname><given-names>H</given-names></name><name><surname>Okumura</surname><given-names>M</given-names></name><name><surname>Tamai</surname><given-names>S</given-names></name><name><surname>Shors</surname><given-names>EC</given-names></name><name><surname>Caplan</surname><given-names>AI</given-names></name></person-group>. <article-title>Marrow cell induced osteogenesis in porous hydroxyapatite and tricalcium phosphate: a comparative histomorphometric study of ectopic bone formation</article-title>. <source>J Biomed Mater Res</source> <year>1990</year>; <volume>24</volume>: <fpage>1563</fpage>–<lpage>1570</lpage>.</citation></ref>
<ref id="bibr77-0885328211406459"><label>77</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>De Aza</surname><given-names>AH</given-names></name><name><surname>Chevalier</surname><given-names>J</given-names></name><name><surname>Fantozzi</surname><given-names>G</given-names></name><name><surname>Schehl</surname><given-names>M</given-names></name><name><surname>Torrecillas</surname><given-names>R</given-names></name></person-group>. <article-title>Crack growth resistance of alumina, zirconia and zirconia toughened alumina ceramics for joint prostheses</article-title>. <source>Biomaterials</source> <year>2002</year>; <volume>23</volume>: <fpage>937</fpage>–<lpage>945</lpage>.</citation></ref>
<ref id="bibr78-0885328211406459"><label>78</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hatton</surname><given-names>A</given-names></name><name><surname>Nevelos</surname><given-names>JE</given-names></name><name><surname>Nevelos</surname><given-names>AA</given-names></name><name><surname>Banks</surname><given-names>RE</given-names></name><name><surname>Fisher</surname><given-names>J</given-names></name><name><surname>Ingham</surname><given-names>E</given-names></name></person-group>. <article-title>Alumina-alumina artificial hip joints Part I: a histological analysis and characterization of wear debris by laser capture microdissection of tissues retrieved at revision</article-title>. <source>Biomaterials</source> <year>2002</year>; <volume>23</volume>: <fpage>3429</fpage>–<lpage>3440</lpage>.</citation></ref>
<ref id="bibr79-0885328211406459"><label>79</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Willmann</surname><given-names>G</given-names></name><name><surname>Fruh</surname><given-names>HJ</given-names></name><name><surname>Pfaff</surname><given-names>HG</given-names></name></person-group>. <article-title>Wear characteristics of sliding pairs of zirconia (Y-TZP) for hip endoprostheses</article-title>. <source>Biomaterials</source> <year>1996</year>; <volume>17</volume>: <fpage>2157</fpage>–<lpage>2162</lpage>.</citation></ref>
<ref id="bibr80-0885328211406459"><label>80</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Eckert</surname><given-names>KL</given-names></name><name><surname>Mathey</surname><given-names>M</given-names></name><name><surname>Mayer</surname><given-names>J</given-names></name><name><surname>Homberger</surname><given-names>FR</given-names></name><name><surname>Thomann</surname><given-names>PE</given-names></name><name><surname>Groscurth</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Preparation and in vivo testing of porous alumina ceramics for cell carrier applications</article-title>. <source>Biomaterials</source> <year>2000</year>; <volume>21</volume>: <fpage>63</fpage>–<lpage>69</lpage>.</citation></ref>
<ref id="bibr81-0885328211406459"><label>81</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Padera</surname><given-names>RF</given-names></name><name><surname>Colton</surname><given-names>CK</given-names></name></person-group>. <article-title>Time course of membrane microarchitecture-driven neovasvularization</article-title>. <source>Biomaterials</source> <year>1996</year>; <volume>17</volume>: <fpage>277</fpage>–<lpage>284</lpage>.</citation></ref>
<ref id="bibr82-0885328211406459"><label>82</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bose</surname><given-names>S</given-names></name><name><surname>Darsell</surname><given-names>J</given-names></name><name><surname>Hosick</surname><given-names>HL</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Sarka</surname><given-names>DK</given-names></name><name><surname>Bandyopadhyay</surname><given-names>A</given-names></name></person-group>. <article-title>Processing and characterization of porous alumina scaffolds</article-title>. <source>J Mater Sci Mater Med</source> <year>2002</year>; <volume>13</volume>: <fpage>23</fpage>–<lpage>28</lpage>.</citation></ref>
<ref id="bibr83-0885328211406459"><label>83</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Karlsson</surname><given-names>M</given-names></name><name><surname>Palsgard</surname><given-names>E</given-names></name><name><surname>Wilshaw</surname><given-names>PR</given-names></name><name><surname>Di Silvio</surname><given-names>L</given-names></name></person-group>. <article-title>Initial in vitro interaction of osteoblasts with nano-porous alumina</article-title>. <source>Biomaterials</source> <year>2003</year>; <volume>24</volume>: <fpage>3039</fpage>–<lpage>3046</lpage>.</citation></ref>
<ref id="bibr84-0885328211406459"><label>84</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Walpole</surname><given-names>AR</given-names></name><name><surname>Xia</surname><given-names>Z</given-names></name><name><surname>Wilson</surname><given-names>CW</given-names></name><name><surname>Triffitt</surname><given-names>JT</given-names></name><name><surname>Wilshaw</surname><given-names>PR</given-names></name></person-group>. <article-title>A novel bano-porous alumina biomaterial with potential for loading with bioactive materials</article-title>. <source>J Biomed Mater Res</source> <year>2009</year>; <volume>90A</volume>: <fpage>46</fpage>–<lpage>54</lpage>.</citation></ref>
<ref id="bibr85-0885328211406459"><label>85</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Drouin</surname><given-names>JM</given-names></name><name><surname>Cales</surname><given-names>B</given-names></name><name><surname>Chevalier</surname><given-names>J</given-names></name><name><surname>Fantozzi</surname><given-names>G</given-names></name></person-group>. <article-title>Fatigue behavior of zirconia hip joint heads experimental results and finite element analysis</article-title>. <source>J Biomed Mater Res</source> <year>1997</year>; <volume>34</volume>: <fpage>149</fpage>–<lpage>155</lpage>.</citation></ref>
<ref id="bibr86-0885328211406459"><label>86</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Helmer</surname><given-names>JD</given-names></name><name><surname>Driskell</surname><given-names>TD</given-names></name></person-group>. <article-title>Research on bioceramics</article-title>. <source>Symposium on Use of Ceramics as Surgical Implants</source>. <publisher-loc>South Carolina</publisher-loc>: <publisher-name>Clemson University</publisher-name>, <year>1969</year>.</citation></ref>
<ref id="bibr87-0885328211406459"><label>87</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Christel</surname><given-names>P</given-names></name><name><surname>Meunier</surname><given-names>A</given-names></name><name><surname>Dorlot</surname><given-names>JM</given-names></name><name><surname>Crolet</surname><given-names>JM</given-names></name><name><surname>Witvoet</surname><given-names>J</given-names></name><name><surname>Sedel</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Biomechanical compatibility and design of ceramic implants for orthopedic Surgery</article-title>. <source>Ann N. Y. Acad Sci</source> <year>1988</year>; <volume>523</volume>: <fpage>234</fpage>–<lpage>256</lpage>.</citation></ref>
<ref id="bibr88-0885328211406459"><label>88</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chevalier</surname><given-names>J</given-names></name></person-group>. <article-title>What future for zirconia as a biomaterial?</article-title>. <source>Biomaterials</source> <year>2006</year>; <volume>27</volume>: <fpage>535</fpage>–<lpage>543</lpage>.</citation></ref>
<ref id="bibr89-0885328211406459"><label>89</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>HW</given-names></name><name><surname>Lee</surname><given-names>SY</given-names></name><name><surname>Bae</surname><given-names>CJ</given-names></name><name><surname>Noh</surname><given-names>YJ</given-names></name><name><surname>Kim</surname><given-names>HE</given-names></name><name><surname>Kim</surname><given-names>HM</given-names></name><etal/></person-group>. <article-title>Porous ZrO<sub>2</sub> bone scaffold coated with hydroxyapatite with fluoroapatite intermediate layer</article-title>. <source>Biomaterials</source> <year>2003</year>; <volume>24</volume>: <fpage>3277</fpage>–<lpage>3284</lpage>.</citation></ref>
<ref id="bibr90-0885328211406459"><label>90</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>HW</given-names></name><name><surname>Kim</surname><given-names>HE</given-names></name><name><surname>Salih</surname><given-names>V</given-names></name><name><surname>Knowles</surname><given-names>JC</given-names></name></person-group>. <article-title>Dissolution control and cellular responses of calcium phosphate coatings on zirconia porous scaffold</article-title>. <source>J Biomed Mater Res</source> <year>2004</year>; <volume>68A</volume>: <fpage>522</fpage>–<lpage>530</lpage>.</citation></ref>
<ref id="bibr91-0885328211406459"><label>91</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>HW</given-names></name><name><surname>Kim</surname><given-names>HE</given-names></name><name><surname>Knowles</surname><given-names>JC</given-names></name></person-group>. <article-title>Hard-tissue-engineered zirconia porous scaffolds with hydroxyapatite sol-gel and slurry coatings</article-title>. <source>J Biomed Mater Res</source> <year>2004</year>; <volume>70B</volume>: <fpage>270</fpage>–<lpage>277</lpage>.</citation></ref>
<ref id="bibr92-0885328211406459"><label>92</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>HW</given-names></name><name><surname>Shin</surname><given-names>SY</given-names></name><name><surname>Kim</surname><given-names>HE</given-names></name><name><surname>Lee</surname><given-names>YM</given-names></name><name><surname>Chung</surname><given-names>CP</given-names></name><name><surname>Lee</surname><given-names>HH</given-names></name><etal/></person-group>. <article-title>Bone formation on the apatite-coated zirconia porous scaffolds within a rabbit calvarial defect</article-title>. <source>J Biomater Appl</source> <year>2008</year>; <volume>22</volume>: <fpage>485</fpage>–<lpage>504</lpage>.</citation></ref>
<ref id="bibr93-0885328211406459"><label>93</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lew</surname><given-names>KS</given-names></name><name><surname>Othman</surname><given-names>R</given-names></name><name><surname>Yeoh</surname><given-names>FY</given-names></name></person-group>. <article-title>Synthesis and characterization of mesoporous hydroxyapatite</article-title>. <source>Adv Sci Tech</source> <year>2010</year>; <volume>63</volume>: <fpage>152</fpage>–<lpage>157</lpage>.</citation></ref>
<ref id="bibr94-0885328211406459"><label>94</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>Z</given-names></name><name><surname>Liao</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>S</given-names></name></person-group>. <article-title>Synthesis of mesoporous hydroxyapatite using a modified hard-templating route</article-title>. <source>Mater Res Bull</source> <year>2009</year>; <volume>44</volume>: <fpage>1626</fpage>–<lpage>1629</lpage>.</citation></ref>
<ref id="bibr95-0885328211406459"><label>95</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>YF</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name></person-group>. <article-title>Triblock polymer templating synthesis of mesostructured hydroxyapatite</article-title>. <source>Microporous Mesoporous Mater</source> <year>2005</year>; <volume>87</volume>: <fpage>110</fpage>–<lpage>117</lpage>.</citation></ref>
<ref id="bibr96-0885328211406459"><label>96</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>J</given-names></name><name><surname>Tjandra</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>YZ</given-names></name><name><surname>Tam</surname><given-names>KC</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Soh</surname><given-names>B</given-names></name></person-group>. <article-title>Hydroxyapatite nanostructure material derived using cationic surfactant as a template</article-title>. <source>J Mater Chem</source> <year>2003</year>; <volume>13</volume>: <fpage>3053</fpage>–<lpage>3057</lpage>.</citation></ref>
</ref-list>
</back>
</article>